

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2016 OF THE CONDITION AND AFFAIRS OF THE

Care Improvement Plus South Central Insurance Company

NAIC Group Cod		ompany Code1256	67 Employer's ID Nur	mber20-3888112	
Organized under the Laws of	(Current) (Prior) Arkansas	, State of Do	omicile or Port of Entry		AR
Country of Domicile	U	nited States of America	a	A	
Licensed as business type:		ife, Accident & Health			
Is HMO Federally Qualified? Yes []	No[]				
Incorporated/Organized	01/13/2006	Comme	enced Business	01/01/2	007
Statutory Home Office 1401		K AT	Little	e Rock , AR, US 72201	
	(Street and Number)		(City or Town	n, State, Country and Zip	Code)
Main Administrative Office		ealth Care Lane MN017 (Street and Number)	7-E900		
	a , MN, US 55343	(Street and Number)		952-936-1300	
(City or Town, Sta	te, Country and Zip Code)		No.	Code) (Telephone Numbe	5.
	Health Care Lane MN017-E900 eet and Number or P.O. Box)			netonka , MN, US 55343 n, State, Country and Zip	100000000000000000000000000000000000000
Primary Location of Books and Records	ADSTRACT	lealth Care Lane MN01	17-E900		300 S C 500 S
	Actor was dispersion	(Street and Number)		952-936-1300	
	a , MN, US 55343 te, Country and Zip Code)		(Area C	Code) (Telephone Number	er)
Internet Website Address		.careimprovementplus	.com	E 3277 (E)	10
	D.1 11 O.4			952-979-6131	
	(Name)		(A	rea Code) (Telephone N	umber)
	carter@uhc.com nail Address)			952-979-7825 (FAX Number)	
		OFFICERS			
President	Timothy John Noel		Treasurer		
Secretary	Kristine Marie Weikel	Chief	Financial Officer	William Jose	ph Hnath
Troy Allen Borca	DIRE	CTORS OR TRUST William Joseph Hnath		Timothy .	lohn Noel
N	State of	Minnesota		State of	
State of Minnesota County of Hennepin	County of	Hennepin		County of	
The officers of this reporting entity being herein described assets were the absolute prelated exhibits, schedules and explanation reporting entity as of the reporting period Statement Instructions and Accounting Prinot related to accounting practices and proofficers also includes the related corresponstatement. The electronic filing may be re-	property of the said reporting entity, free a is therein contained, annexed or referred to stated above, and of its income and deduc- actices and Procedures manual except to to the control of the process of the control of the control of the control of the control of the deline electronic filing with the NAIC, who	and clear from any liens of too, is a full and true stater tions there from for the p the extent that: (1) state la formation, knowledge and en required, that is an exi- in addition to the enclose	or claims thereon, except as ment of all the assets and lia beriod ended, and have been aw may differ; or, (2) that s il belief; respectively. Furt act copy (except for format ed statement.	abilities and of the condition in completed in accordance state rules or regulations received.	with the NAIC Annual pure differences in reporting
Timothy John Noel		Kristine Marie Weike	1		
President		Secretary			
Subscribed and swom to before me this 24th day of Januar Churyl A. Gorda Cheryl L. Tordo	y 2017 Acre Nan Nan NANCY NOTARY PL	ay L. Jae	a. Is this an original filing? b. If no. 1. State the amendment	da	Yes [X] No []
CHERYL L. NOTARY PUBLIC My Commiss January 3	JORDAN - MINNESOTA ion Expires 1, 2018	mum		ached	

ASSETS

			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)			339,353,876	
2.	Stocks (Schedule D):				,100,140,000
۷.	2.1 Preferred stocks	0	0	0	0
	2.2 Common stocks		0		
3.	Mortgage loans on real estate (Schedule B):				
J.	3.1 First liens	0	0	0	0
	3.2 Other than first liens.		0		0
4.	Real estate (Schedule A):				
٦.	4.1 Properties occupied by the company (less \$				
	encumbrances)	0	L0	0	0
	4.2 Properties held for the production of income (less				
	\$0 encumbrances)	0	L0	0	0
	4.3 Properties held for sale (less \$0				
	encumbrances)	0	L0	0	0
_		0			0
5.	Cash (\$235,128,988 , Schedule E - Part 1), cash equivalents				
	(\$	050 404 000		050 404 000	00 047 407
	investments (\$15,365,292 , Schedule DA)				
6.	Contract loans, (including \$				
7.	Derivatives (Schedule DB)				
8.	Other invested assets (Schedule BA)				
9.	Receivables for securities				
10.	Securities lending reinvested collateral assets (Schedule DL)				
11.	Aggregate write-ins for invested assets				
12.	Subtotals, cash and invested assets (Lines 1 to 11)				
13.	Title plants less \$0 charged off (for Title insurers				
	only)				
14.	Investment income due and accrued	3,114,486	0	3,114,486	4,072,041
15.	Premiums and considerations:	7 005 400	0 044 004	4 504 405	470.050
	15.1 Uncollected premiums and agents' balances in the course of collection		6,341,281	1,584,185	1/2,352
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$0	0			0
	earned but unbilled premiums)	0	<u> </u> U	U	0
	15.3 Accrued retrospective premiums (\$	208.246.141		000 040 444	100 500 040
40	contracts subject to redetermination (\$208,301,891)	200,240, 141	0	208,246,141	108,560,046
16.	Reinsurance:	00.070		00.070	0
	16.1 Amounts recoverable from reinsurers			20,070	0
	16.2 Funds held by or deposited with reinsured companies			0	0 0
47	16.3 Other amounts receivable under reinsurance contracts				
17.	Amounts receivable relating to uninsured plans				2,692,040
18.1	g .		0	4,653,117 20,769,491	
	Net deferred tax asset		0	20,769,491	_
19.	Electronic data processing equipment and software				0
20.		0		0	0
21.	Furniture and equipment, including health care delivery assets (\$	0	0	0	0
22	(\$				0
22. 23.	Receivables from parent, subsidiaries and affiliates		0		0
23. 24.	Health care (\$128,203,156) and other amounts receivable	176 061 1/1	//Q 757 005	0	
	Aggregate write-ins for other than invested assets				
25. 26.	Aggregate write-ins for other than invested assets	∠4,943	1,009	∠ა, ყა4	
20.	Protected Cell Accounts (Lines 12 to 25)	1,084,781,192	55,290,383	1,029,490,809	900,901,751
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0	0
28.	Total (Lines 26 and 27)	1,084,781,192	55,290,383	1,029,490,809	900,901,751
20.	DETAILS OF WRITE-INS	1,004,701,102	00,200,000	1,020,400,000	000,001,701
4404					
1101.					
1102.					
1103.			-		-
1198.	Summary of remaining write-ins for Line 11 from overflow page		0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0	0
2501.	State Income Tax Receivable		0		3,043,337
2502.	Micellaneous Receivables		1,009	0	0
2503.					
2598.	Summary of remaining write-ins for Line 25 from overflow page				0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	24,943	1,009	23,934	3,043,337

LIABILITIES, CAPITAL AND SURPLUS

	LIADILITIES, CAF		Current Year		Prior Year
	<u> </u>	1	2	3	4
					T.11.1
	44.00	Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$111,213 reinsurance ceded)			519,608,714	
2.	Accrued medical incentive pool and bonus amounts		0		
3.	Unpaid claims adjustment expenses	4,781,900	0	4,781,900	3,555,613
4.	Aggregate health policy reserves, including the liability of				
	\$7,158,971 for medical loss ratio rebate per the Public				
	Health Service Act				
5.	Aggregate life policy reserves				
6.	Property/casualty unearned premium reserves.				
7.	Aggregate health claim reserves	536,656	0	536,656	11,186
8.	Premiums received in advance	915,918	0	915,918	323,875
9.	General expenses due or accrued		0	4,467,651	7,586,035
10.1					
	(including \$0 on realized capital gains (losses))	0	0	0	0
10.2	Net deferred tax liability				
11.	Ceded reinsurance premiums payable				
12.	Amounts withheld or retained for the account of others				
13.	Remittances and items not allocated.				
			0	1,307,313	2,274,330
14.	Borrowed money (including \$0 current) and				
	interest thereon \$0 (including	_			
	\$0 current)				
15.	Amounts due to parent, subsidiaries and affiliates				
16.	Derivatives			0	0
17.	Payable for securities.				0
18.	Payable for securities lending	0	0	0	0
19.	Funds held under reinsurance treaties (with \$0				
	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$0 certified reinsurers)	0	0	0	0
20.	Reinsurance in unauthorized and certified (\$0)				
	companies	0	0	0	0
21.	Net adjustments in assets and liabilities due to foreign exchange rates				0
22.	Liability for amounts held under uninsured plans.			4,657,092	
	Aggregate write-ins for other liabilities (including \$	4,007,002		4,007,002	140,000
25.	current)	60 152	0	60 152	576 042
0.4	Total liabilities (Lines 1 to 23).				
24.					
25.	Aggregate write-ins for special surplus funds				
26.	Common capital stock				
27.	Preferred capital stock				
28.	Gross paid in and contributed surplus.				
29.	Surplus notes				
30.	Aggregate write-ins for other than special surplus funds	XXX	XXX	0	0
31.	Unassigned funds (surplus)	xxx	XXX	239,501,278	72,496,950
32.	Less treasury stock, at cost:				
	32.10 shares common (value included in Line 26				
	\$	XXX	XXX	0	0
	32.20 shares preferred (value included in Line 27				
	\$	XXX	XXX	0	0
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)				
		XXX	XXX	1,029,490,809	900,901,751
34.	Total liabilities, capital and surplus (Lines 24 and 33)	^^^	AAA	1,023,430,003	300,301,731
	DETAILS OF WRITE-INS	00.450		00.450	570.040
	Unclaimed Property				
2398.	Summary of remaining write-ins for Line 23 from overflow page				
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	69,153	0	69,153	576,943
2501.	Section 9010 ACA Subsequent Fee Year Assessment	xxx	XXX	0	59,091,827
2502.		xxx	XXX		
2503.		xxx	XXX		
	Summary of remaining write-ins for Line 25 from overflow page				
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	59,091,827
	Totals (Lines 2501 tind 2505 plus 2590)(Line 25 above)			-	· · ·
	Summary of remaining write-ins for Line 30 from overflow page				0
3099.	Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

		Currer	nt Year	Prior Year
		1 Uncovered	2 Total	3 Total
1.	Member Months			3,046,126
2. 1	Net premium income (including \$0 non-health premium income)	xxx	3,681,268,051	3,310,964,680
3. (Change in unearned premium reserves and reserve for rate credits	xxx	24,062,913	(20,693,283)
4. F	Fee-for-service (net of \$0 medical expenses)	xxx	0	0
5. F	Risk revenue	xxx	0	0
6. <i>A</i>	Aggregate write-ins for other health care related revenues	xxx	0	0
7. <i>F</i>	Aggregate write-ins for other non-health revenues	xxx	0	0
8. 7	Total revenues (Lines 2 to 7)	xxx	3,705,330,964	3,290,271,397
	Hospital and Medical:			
	Hospital/medical benefits			
	Other professional services			
	Outside referrals			0
	Emergency room and out-of-area			0
	Prescription drugs			
	Aggregate write-ins for other hospital and medical			
15. l	ncentive pool, withhold adjustments and bonus amounts	0	5,252,806	13,949,043
16. 8	Subtotal (Lines 9 to 15)	0	2,835,338,205	2,783,085,240
	Less:			
	Net reinsurance recoveries			0
	Total hospital and medical (Lines 16 minus 17)			
	Non-health claims (net)			
	Claims adjustment expenses, including \$82,308,420 cost containment expenses			
21. (General administrative expenses	0	338,570,400	288,685,891
22. I	ncrease in reserves for life and accident and health contracts (including \$0			
	increase in reserves for life only)			
	Total underwriting deductions (Lines 18 through 22)			
	Net underwriting gain or (loss) (Lines 8 minus 23)			
	Net investment income earned (Exhibit of Net Investment Income, Line 17)			
	Net realized capital gains (losses) less capital gains tax of \$			
	Net investment gains (losses) (Lines 25 plus 26)	0	11, 143, 869	10,786,312
28. N	Net gain or (loss) from agents' or premium balances charged off [(amount recovered			
	\$(5,237,745))](5,237,745)			
	Aggregate write-ins for other income or expenses	0	(1,430)	0
	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)			82,992,605
31. F	Federal and foreign income taxes incurred	XXX	159,784,303	47,655,309
32. N	Net income (loss) (Lines 30 minus 31)	XXX	241,424,946	35,337,296
	DETAILS OF WRITE-INS			
0601				
0603				
	Summary of remaining write-ins for Line 6 from overflow page		0	0
	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXXXX		0
0702				
	Summary of remaining write-ins for Line 7 from overflow page			0
	Fotals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	xxx	0	0
1402				
1403				
1498.	Summary of remaining write-ins for Line 14 from overflow page	0	0	0
	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901. F	ines and Penalties	0	(1,430)	0
2902				
2903				
	Summary of remaining write-ins for Line 29 from overflow page		0	0
2999. 1	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	(1,430)	0

STATEMENT OF REVENUE AND EXPENSES (Continued)

	STATEMENT OF REVENUE AND EXPENSES	4	,
		Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	315, 151,737	348,584,843
34.	Net income or (loss) from Line 32	241,424,946	35,337,296
35.	Change in valuation basis of aggregate policy and claim reserves	0	0
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$	0	0
37.	Change in net unrealized foreign exchange capital gain or (loss)		0
38.	Change in net deferred income tax		2,944,527
39.	Change in nonadmitted assets	(9,262,484)	(6,714,929)
40	Change in unauthorized and certified reinsurance		
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles.	0	0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend).	0	0
	44.3 Transferred to surplus	0	0
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)	0	0
	45.3 Transferred from capital	0	0
46.	Dividends to stockholders	(150,000,000)	(65,000,000
47.	Aggregate write-ins for gains or (losses) in surplus	21,995,512	0
48.	Net change in capital and surplus (Lines 34 to 47)	107,912,501	(33,433,106
49.	Capital and surplus end of reporting period (Line 33 plus 48)	423,064,238	315, 151, 737
	DETAILS OF WRITE-INS		
4701.	Correction of prior year error	21,995,512	0
4702.			
4703.		-	
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	21,995,512	0

Cash from Operations
Premiums collected net of reinsurance 3,577,709,129 3,263,754,02
1. Premiums collected net of reinsurance 3, 577, 709, 129 3, 263, 754, 0 2. Net Investment Income 16, 966, 136 15, 959, 2 3. Miscellaneous income 0 4. Total (Lines 1 through 3) 3, 394,675, 265 3, 279,713, 2 5. Benefit and loss related payments 2, 667,573, 379 2, 686, 174, 8 6. Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts 0 7. Commissions, expenses paid and aggregate write-ins for deductions 407,618, 096 476, 545, 1 8. Dividends paid to policyholders 0 9. Federal and foreign income taxes paid (recovered) net of \$ 0 tax on capital gains (losses) 174, 492, 117 35, 382, 4 10. Total (Lines 5 through 9) 3, 229, 643, 392 3, 198, 072, 4 11. Net cash from operations (Line 4 minus Line 10) 345, 031, 673 81, 640, 7 **Cash from Investments** **Cash from Investments** **Cash from Investments sold, matured or repaid: 12. Proceeds from investments sold, matured or repaid: 12. Bonds 350, 436, 383 259, 179, 5 12.2 Stocks 0 12.3 Mortgage loans 0 12.4 Real estate 0 12.5 Other invested assets 0 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments 0 12.7 Miscellaneous proceeds 0 12.8 Total investment proceeds (Lines 12.1 to 12.7) 350, 436, 393 259, 179, 5 13. Cost of investments acquired (long-term only): 13.1 Bonds 200, 656, 596 271, 492, 7 13.2 Stocks 0 13.3 Mortgage loans 0 13.4 Real estate 0 13.6 Other invested assets 0 13.6 Niscellaneous approaceds 0 13.6 Niscellaneous applications 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 280,696, 596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0 14. Net increase (decrease) in contract loans and premium notes 0 15. Proceeds (Lines 13.1 to 13.6) 0 15. Proceeds 171,492,7 15. Net increase (decrease) in contract loans and premium notes 0 15. Proceeds 171,492,7 15. Proceeds 172,192,7 15. Proceeds 173,192,7 15. Proceeds 173,192,7 1
2. Net investment income .16,966,136 .15,969,136 .26,667,573,379 .2,686,174,8 .16,169 .16,169 .16,169 .16,169 .16,169 .16,169 .16,169 .16,174 .17,171 .16,169 .17,171 .16,169 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,171 .17,
3. Miscellaneous income
Total (Lines 1 through 3) 3.594,675,265 3.279,713,2
5. Benefit and loss related payments 2,667,573,379 2,686,174,8 6. Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts 0 7. Commissions, expenses paid and aggregate write-ins for deductions 407,618,096 476,545,1 8. Dividends paid to policyholders 0 0 9. Federal and foreign income taxes paid (recovered) net of \$
6. Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts 0 7. Commissions, expenses paid and aggregate write-ins for deductions 407,618,096 476,545,1 8. Dividends paid to policyholders 0 0 9. Federal and foreign income taxes paid (recovered) net of \$ 0 tax on capital gains (losses) 174,452,117 35,352,4 10. Total (Lines 5 through 9) 3,249,643,592 3,198,072,4 11. Net cash from operations (Line 4 minus Line 10) 345,031,673 81,640,7 Cash from Investments Cash from Investments 12. Bonds 350,436,393 259,179,5 12.2 Stocks 0 0 12.3 Mortgage loans 0 0 12.5 Other invested assets 0 0 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments 0 0 12.8 Total investment proceeds (Lines 12.1 to 12.7) 350,436,393 259,179,5 13. Cost of investments acquired (long-term only): 350,436,393 259,179,5 13. Donds 208,056,596 271,492,7 13.2 Stocks 0 0 13.3
7. Commissions, expenses paid and aggregate write-ins for deductions 407,618,096 476,545,1 8. Dividends paid to policyholders 0 0 9. Federal and foreign income taxes paid (recovered) net of \$
8. Dividends paid to policyholders 0 9. Federal and foreign income taxes paid (recovered) net of \$
9. Federal and foreign income taxes paid (recovered) net of \$ 0 tax on capital gains (losses) 174,452,117 35,352,4 10. Total (Lines 5 through 9) 3,249,643,592 3,198,072,4 11. Net cash from operations (Line 4 minus Line 10) 345,031,673 81,640,7
10. Total (Lines 5 through 9)
11. Net cash from operations (Line 4 minus Line 10). 345,031,673 81,640,73
Cash from Investments 12. Proceeds from investments sold, matured or repaid: 12.1 Bonds .350,436,393 .259,179,5 12.2 Stocks .0 12.3 Mortgage loans .0 12.4 Real estate .0 12.5 Other invested assets .0 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments 12.7 Miscellaneous proceeds 12.8 Total investment proceeds (Lines 12.1 to 12.7) 13. Cost of investments acquired (long-term only): 13.1 Bonds 13.2 Stocks 13.4 Real estate 13.5 Other invested assets 13.6 Miscellaneous applications <
12. Proceeds from investments sold, matured or repaid: 350,436,393 259,179,5 12.1 Bonds 350,436,393 259,179,5 12.2 Stocks 0 0 12.3 Mortgage loans 0 0 12.4 Real estate 0 0 12.5 Other invested assets 0 0 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments 0 0 12.7 Miscellaneous proceeds 0 0 12.8 Total investment proceeds (Lines 12.1 to 12.7) 350,436,393 259,179,5 13. Cost of investments acquired (long-term only): 208,056,596 271,492,7 13.1 Bonds 208,056,596 271,492,7 13.2 Stocks 0 0 13.3 Mortgage loans 0 0 13.4 Real estate 0 0 13.5 Other invested assets 0 0 13.6 Miscellaneous applications 0 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
12.1 Bonds 350,436,393 259,179,5 12.2 Stocks 0 0 12.3 Mortgage loans 0 0 12.4 Real estate 0 0 12.5 Other invested assets 0 0 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments 0 0 12.7 Miscellaneous proceeds 0 0 12.8 Total investment proceeds (Lines 12.1 to 12.7) 350,436,393 259,179,5 13. Cost of investments acquired (long-term only): 208,056,596 271,492,7 13.1 Bonds 208,056,596 271,492,7 13.2 Stocks 0 0 13.3 Mortgage loans 0 0 13.4 Real estate 0 0 13.5 Other invested assets 0 0 13.6 Miscellaneous applications 0 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
12.2 Stocks 0 12.3 Mortgage loans 0 12.4 Real estate 0 12.5 Other invested assets 0 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments 0 12.7 Miscellaneous proceeds 0 12.8 Total investment proceeds (Lines 12.1 to 12.7) 350,436,393 259,179,5 13. Cost of investments acquired (long-term only): 208,056,596 271,492,7 13.2 Stocks 0 0 13.3 Mortgage loans 0 0 13.4 Real estate 0 0 13.5 Other invested assets 0 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
12.3 Mortgage loans 0 12.4 Real estate 0 12.5 Other invested assets 0 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments 0 12.7 Miscellaneous proceeds 0 12.8 Total investment proceeds (Lines 12.1 to 12.7) 350,436,393 259,179,5 13. Cost of investments acquired (long-term only): 208,056,596 .271,492,7 13.2 Stocks 0 13.3 Mortgage loans 0 13.4 Real estate 0 13.5 Other invested assets 13.6 Miscellaneous applications 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 14. Net increase (decrease) in contract loans and premium notes 0
12.4 Real estate 0 12.5 Other invested assets 0 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments 0 12.7 Miscellaneous proceeds 0 12.8 Total investment proceeds (Lines 12.1 to 12.7) 350,436,393 259,179,5 13. Cost of investments acquired (long-term only): 208,056,596 .271,492,7 13.2 Stocks .0 13.3 Mortgage loans 13.4 Real estate 13.5 Other invested assets 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 14. Net increase (decrease) in contract loans and premium notes 0
12.5 Other invested assets 0 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments 0 12.7 Miscellaneous proceeds 0 12.8 Total investment proceeds (Lines 12.1 to 12.7) 350,436,393 259,179,5 13. Cost of investments acquired (long-term only): 13.1 Bonds 208,056,596 13.2 Stocks 0 13.3 Mortgage loans 0 13.4 Real estate 0 13.5 Other invested assets 0 13.6 Miscellaneous applications 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
12.6 Net gains or (losses) on cash, cash equivalents and short-term investments .0 12.7 Miscellaneous proceeds 0 12.8 Total investment proceeds (Lines 12.1 to 12.7) 350,436,393 259,179,5 13. Cost of investments acquired (long-term only): 208,056,596 271,492,7 13.1 Bonds 208,056,596 271,492,7 13.2 Stocks .0 13.4 Real estate .0 13.5 Other invested assets .0 13.6 Miscellaneous applications 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
12.7 Miscellaneous proceeds 0 12.8 Total investment proceeds (Lines 12.1 to 12.7) 350,436,393 259,179,5 13. Cost of investments acquired (long-term only): 208,056,596 271,492,7 13.1 Bonds 208,056,596 271,492,7 13.2 Stocks 0 0 13.4 Real estate 0 0 13.5 Other invested assets 0 0 13.6 Miscellaneous applications 0 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
12.8 Total investment proceeds (Lines 12.1 to 12.7) 350,436,393 259,179,5 13. Cost of investments acquired (long-term only): 208,056,596 .271,492,7 13.1 Bonds .208,056,596 .271,492,7 13.2 Stocks .0 13.4 Real estate 13.5 Other invested assets 13.6 Miscellaneous applications 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
13. Cost of investments acquired (long-term only): 208,056,596 271,492,7 13.1 Bonds
13.1 Bonds 208,056,596 271,492,7 13.2 Stocks 0 13.3 Mortgage loans 0 13.4 Real estate 0 13.5 Other invested assets 0 13.6 Miscellaneous applications 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
13.2 Stocks 0 13.3 Mortgage loans 0 13.4 Real estate 0 13.5 Other invested assets 0 13.6 Miscellaneous applications 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
13.3 Mortgage loans 0 13.4 Real estate 0 13.5 Other invested assets 0 13.6 Miscellaneous applications 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
13.4 Real estate 0 13.5 Other invested assets 0 13.6 Miscellaneous applications 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
13.5 Other invested assets 0 13.6 Miscellaneous applications 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
13.6 Miscellaneous applications 0 13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
13.7 Total investments acquired (Lines 13.1 to 13.6) 208,056,596 271,492,7 14. Net increase (decrease) in contract loans and premium notes 0
14. Net increase (decrease) in contract loans and premium notes
15. Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14). 142.270.707 (19. 212.2
19. Not odds non investments (Line 12.0 minus Line 19.7 minus Line 14)
Cash from Financing and Miscellaneous Sources
16. Cash provided (applied):
16.1 Surplus notes, capital notes0
16.2 Capital and paid in surplus, less treasury stock
16.3 Borrowed funds
16.4 Net deposits on deposit-type contracts and other insurance liabilities
16.5 Dividends to stockholders65,000,00
16.6 Other cash provided (applied)
17. Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)
RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS
18. Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)
19. Cash, cash equivalents and short-term investments:
19.1 Beginning of year
19.2 End of year (Line 18 plus Line 19.1) 250,494,280 68,217,4

Note: Supplemental disclosures of cash flow information for non-cash transactions:		

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

1 2 3 4 5 6 7 8 9	
Total	0 0
2. Change in unearned premium reserves and reserve for rate credit revenues (net of \$ 0	XXX
2. Change in unearned premium reserves and reserve for rate credit revenues	XXX
3. Fee-for-service (net of \$	
4. Risk revenue	
5. Aggregate write-ins for other health care related revenues 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	XXX
revenues	1
revenues	xxx
8. Hospital/medical benefits 2,682,323,471 0 0 0 0 0 2,682,323,471 0 0 0 0 0 2,682,323,471 0 </td <td>0</td>	0
9. Other professional services 7,430,754 0 0 0 0 0 0 7,430,754 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
10. Outside referrals 0	
11. Emergency room and out-of-area 0	
12. Prescription drugs .140,331,174 .0 <td></td>	
13. Aggregate write-ins for other hospital and medical 0	
14. Incentive pool, withhold adjustments and bonus amounts 5,252,806 0 0 0 0 0 0 5,252,806 0 0 15. Subtotal (Lines 8 to 14) 2,835,338,205 0 0 0 0 0 0 2,835,338,205 0 0 16. Net reinsurance recoveries 599,723 0 0 0 0 0 599,723 0 0	
15. Subtotal (Lines 8 to 14)	
16. Net reinsurance recoveries	
17 Total medical and hospital (Lines 15 minus 16) 2 894 738 /89 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	XXX
	XXX
18. Non-health claims (net)	0 '
19. Claims adjustment expenses including	!
\$	0
20. General administrative expenses	0
21. Increase in reserves for accident and health contracts	XXX
22. Increase in reserves for life contracts0XX _	0 '
23. Total underwriting deductions (Lines 17 to 22)	
24. Total underwriting gain or (loss) (Line 7 minus Line 23) 395,053,682 0 0 0 0 0 395,052,929 0 753	0
DETAILS OF WRITE-INS 0501.	XXX
0502	XXX
0503.	L XXX
0598. Summary of remaining write-ins for Line 5 from overflow page 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	XXX
D599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	
0601	////
0602	
0603.	†
0698. Summary of remaining write-ins for Line 6 from overflow	†
page0 XXXXXX	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above) 0 XXX XXX	0
1301.	XXX
1302.	XXX
1303.	XXX
1398. Summary of remaining write-ins for Line 13 from overflow page	
1399. Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above) 0 0 0 0 0 0 0 0 0	

_

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

PART 1 - PREMIUMS				
	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical)	0	0	0	0
Medicare Supplement	0	0	0	0
		0	0	0
3. Dental only	0	0	0	0
A Vision only	0	0	0	0
4. Vision only		0		
5. Federal Employees Health Benefits Plan	0	0	0	0
5. Tederal Employees Tearri Deficition 1 fair				
6. Title XVIII - Medicare	3,681,663,451	0	395.400	3,681,268,051
				, 55 . , 255 , 55
7. Title XIX - Medicaid	0	0	0	0
8. Other health	0	0	0	0
9. Health subtotal (Lines 1 through 8)	3,681,663,451	0	395,400	3,681,268,051
10. Life	0	0	0	0
	_	_		
11. Property/casualty	0	0	0	0
	0 004 000 454	2	005 400	0 004 000 054
12. Totals (Lines 9 to 11)	3,681,663,451	0	395,400	3,681,268,051

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

				FAILI 2 - CLA	IMS INCURRED DUF	WING THE TEAK					
		1	2	3	4	5	6 Federal	7	8	9	10
		Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1.	Payments during the year:		(, , ,	,					
• • •	1.1 Direct	2,663,591,666	0	0	0	0	0	2,663,591,666	0	0	0
	1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	
	1.3 Reinsurance ceded	468,224	0	0	0	0	0	468,224	0	0	0
	1.4 Net	2,663,123,442	0	0	0	0	0	2,663,123,442	0	0	0
2.		4,449,937	0	0	0	0	0	4,449,937	0	0	
	Claim liability December 31, current year from Part 2A:							.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
٥.	3.1 Direct	519,719,927	0	0	0	0	0	519,719,927	0	0	0
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	3.3 Reinsurance ceded	111,213	0	0	0	0	0	111,213	0	0	0
	3.4 Net	519,608,714	0	0	0	0	0	519,608,714	0	0	C
4	Claim reserve December 31, current year from Part 2D:										
•	4.1 Direct	536,872	0	0	0	0	0	536,872	0	0	0
	4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	4.3 Reinsurance ceded	216	0	0	0	0	0	216	0	0	
	4.4 Net	536,656	0	0	0	0	0	536,656	0	0	0
5.	Accrued medical incentive pools and bonuses, current	,									
	year	13,087,735	0	0	0	0	0	13,087,735	0	0	0
6.	Net healthcare receivables (a)	29,461,701	0	0	0	0	0	29,461,701	0	0	0
7.	Amounts recoverable from reinsurers December 31, current year	20,070	0	0	0	0	0	20,070	0	0	ſ
8.	•	20,070	u				0	20,070			
0.	8.1 Direct	324,290,179	0	٥	١	0	0	324,290,179	0	٥	0
	8.2 Reinsurance assumed		Δ	٥	ا ا	٥	0				
	8.3 Reinsurance ceded	0	o	٠	ا ا	٠	0	Δ			
	8.4 Net	324,290,179		٥	ا ا			324,290,179	۰		
9	Claim reserve December 31, prior year from Part 2D:				U	0	0				
9.	9.1 Direct	11,186	0	0	١	0	0	11.186	0	٥	0
	9.2 Reinsurance assumed	11, 100	o	٥	ا ،	٥		Λ		 n	
	9.3 Reinsurance ceded	٥	Λ	٥	n l	٠	o	0		n	
	9.4 Net	11,186	o	٠	n l	٥	0	11.186			
10.	Accrued medical incentive pools and bonuses, prior year	12.284.866	o		۰	٥		12.284.866	o	 n	
	Amounts recoverable from reinsurers December 31,	12,204,000	U	0	0	<u> </u>	U	12,204,000	U	0	
11.	prior year	0	0	0	0	0	0	0	0	0	0
12	Incurred Benefits:								5		
	12.1 Direct	2,830,085,399	0	0	0	0	0	2,830,085,399	0	0	
	12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	12.3 Reinsurance ceded	599,723	0	0	0	0	0	599,723	0	0	0
	12.4 Net	2,829,485,676	0	0	0	0	0		0	0	C
13	Incurred medical incentive pools and bonuses	5,252,806	0	0	0	0	0	5,252,806	0	0	C

⁽a) Excludes \$0 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

				IS LIABILITY LIND			_	•		10
	1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Health Benefits Plan	XVIII Medicare	XIX Medicaid	Other Health	Other Non-Health
Reported in Process of Adjustment:										
1.1 Direct	137,560,900	0	0	0	0	0	137,560,900	0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	6,496	0	0	0	0	0	6,496	0	0	0
1.4 Net	137,554,404	0	0	0	0	0	137,554,404	0	0	0
Incurred but Unreported:										
2.1 Direct	379,101,770	0	0	0	0	0	379,101,770	0	0	0
2.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
2.3 Reinsurance ceded	104,717	0	0	0	0	0	104,717	0	0	0
2.4 Net	378,997,053	0	0	0	0	0	378,997,053	0	0	0
Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	3,057,257	0	0	0	0	0	3,057,257	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
3.4 Net	3,057,257	0	0	0	0	0	3,057,257	0	0	0
4. TOTALS:										
4.1 Direct	519,719,927	0	0	0	0	0	519,719,927	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	111,213	0	0	0	0	0	111,213	0	0	0
4.4 Net	519,608,714	0	0	0	0	0	519,608,714	0	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

FART 2B - ANALTSIS OF CLAIMS UNFAID - FRIC				and Claim Liability	5	6
	Claims Paid D	Ouring the Year		of Current Year		Fating at a d Olaina
	1	2	3	4		Estimated Claim Reserve and Claim
	On Claims Incurred		On Claims Unpaid		Claims Incurred	Liability
	Prior to January 1	On Claims Incurred	December 31 of	On Claims Incurred	In Prior Years	December 31 of
Line of Business	of Current Year	During the Year	Prior Year	During the Year	(Columns 1 + 3)	Prior Year
Comprehensive (hospital and medical)	0	0	0	0	0	0
Medicare Supplement	0	0	0	0	0	0
3. Dental Only	0	0	0	0	0	0
4. Vision Only	0	0	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0	0	0
6. Title XVIII - Medicare	173,035,128	2,490,068,245	46,502,824	473,642,546	219,537,952	324,301,365
7 Title XIX - Medicaid	0	0	0	0	0	0
8. Other health	0	0	0	0	0	0
9. Health subtotal (Lines 1 to 8)	173,035,128	2,490,068,245	46,502,824	473,642,546	219,537,952	324,301,365
10. Healthcare receivables (a)	35,268,301	129,250,043	0	12,442,797	35,268,301	147,499,440
11. Other non-health	0	0	0	0	0	0
12. Medical incentive pools and bonus amounts	3,756,013	693,924	4,092,352	8,995,383	7,848,365	12,284,866
13. Totals (Lines 9 - 10 + 11 + 12)	141,522,840	2,361,512,126	50,595,176	470, 195, 132	192,118,016	189,086,791

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (000 Omitted)

Section A - Paid Health Claims - Title XVIII

		Cun	nulative Net Amounts P	aid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2012	2013	2014	2015	2016
1. Prior	112,464	112,464	107,686	103,448	102,825
2. 2012	1,067,769	1,136,613	1,132,332	1, 128, 694	1, 128, 061
3. 2013	XXX	1,949,986	2,080,216	2,078,515	2,076,658
4. 2014	XXX	XXX	2,354,298	2,519,280	2,513,927
5. 2015	XXX	XXX	XXX	2,530,771	2,716,029
6. 2016	XXX	XXX	XXX	XXX	2,490,782

Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonus Outstanding at End of Year					
	1	2	3	4	5	
Year in Which Losses Were Incurred	2012	2013	2014	2015	2016	
1. Prior	114,342	112,464	107,686	103,448	102,825	
2. 2012	1,210,155	1, 139, 531	1,132,332	1,128,694	1,128,061	
3. 2013	XXX	2,129,673	2,062,734	2,078,515	2,076,658	
4. 2014	XXX	XXX	2,570,478	2,525,551	2,513,927	
5. 2015	XXX	XXX	XXX	2,861,086	2,766,624	
6. 2016	XXX	XXX	XXX	XXX	2,973,420	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2012	1,650,933	1,128,061	103,406	9.2	1,231,467	74.6	0	0	1,231,467	74.6
2.	2013	2,464,373	2,076,658	88,247	4.2	2,164,905	87.8	0	0	2,164,905	87.8
3.	2014	2,985,409	2,513,927	68,349	2.7	2,582,276	86.5	0	0	2,582,276	86.5
4.	2015	3,290,271	2,716,029	142,756	5.3	2,858,785	86.9	50,595	454	2,909,834	88.4
5.	2016	3,705,331	2,490,782	133,988	5.4	2,624,770	70.8	482,638	4,328	3,111,736	84.0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (000 Omitted)

Section A - Paid Health Claims - Grand Total

			Cumi	ulative Net Amounts P	aid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2012	2013	2014	2015	2016
1.	Prior	112,464	112,464	107,686	103,448	102,825
2.	2012	1,067,769	1, 136, 613	1, 132, 332	1, 128, 694	1, 128, 061
3.	2013	XXX	1,949,986	2,080,216	2,078,515	2,076,658
4.	2014	XXX	XXX	2,354,298	2,519,280	2,513,927
5.	2015	XXX	XXX	XXX	2,530,771	2,716,029
6.	2016	XXX	XXX	XXX	XXX	2,490,782

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonus Outstanding at End of Year					
Year in Which Losses Were Incurred	1 2012	2 2013	3 2014	4 2015	5 2016	
	114.342	112.464	107.686	103.448	102.825	
1. Prior	7	, ,			, .	
2. 2012	1,210,155	1,139,531	1,132,332	1,128,694	1,128,061	
3. 2013	XXX	2,129,673	2,062,734	2,078,515	2,076,658	
4. 2014	XXX	XXX	2,570,478	2,525,551	2,513,927	
5. 2015	XXX	XXX	XXX	2,861,086	2,766,624	
6. 2016	XXX	XXX	XXX	XXX	2,973,420	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2012	1,650,933	1,128,061	103,406	9.2	1,231,467	74.6	00	0	1,231,467	74.6
2.	2013	2,464,373	2,076,658	88,247	4.2	2,164,905	87.8	0	0	2,164,905	87.8
3.	2014	2,985,409	2,513,927	68,349	2.7	2,582,276	86.5	0	0	2,582,276	86.5
4.	2015	3,290,271	2,716,029	142,756	5.3	2,858,785	86.9	50,595	454	2,909,834	88.4
5.	2016	3,705,331	2,490,782	133,988	5.4	2,624,770	70.8	482,638	4,328	3,111,736	84.0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	PART 2D - A	GGREGATE RESER	VE FOR ACCIDENT	<u> </u>	NTRACTS ONLY				
	1	2 Comprehensive	3 Medicare	4	5	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9
	Total	(Hospital & Medical)	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Other
Unearned premium reserves	0	0	0	0	0	0	0	0	c
Additional policy reserves (a)	0	0	0	0	0	0	0	0	
Reserve for future contingent benefits	0	0	0	0	0	0	0	0	c
Reserve for rate credits or experience rating refunds (including									
\$0) for investment income	10,558,209	0	0	0	0	0	10,558,209	0	c
Aggregate write-ins for other policy reserves	0	0	0	0	0	0	0	0	c
6. Totals (gross)	10,558,209	0	0	0	0	0	10,558,209	0	c
7. Reinsurance ceded	0	0	0	0	0	0	0	0	c
8. Totals (Net)(Page 3, Line 4)	10,558,209	0	0	0	0	0	10,558,209	0	
Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	
10. Reserve for future contingent benefits	536,872	0	0	0	0	0	536,872	0	C
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	
12. Totals (gross)	536,872	0	0	0	0	0	536,872	0	c
13. Reinsurance ceded	216	0	0	0	0	0	216	0	
14. Totals (Net)(Page 3, Line 7)	536,656	0	0	0	0	0	536,656	0	(
DETAILS OF WRITE-INS									
0501.									
0502.									
0503.									
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	C
1101.									
1102.									
1103.									
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	c
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	

(a) Includes \$ ______0 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

	T		YSIS OF EXPENSE			1
		Claim Adjustm 1 Cost Containment	2 Other Claim Adjustment	3 General Administrative	4 Investment	5
	_	Expenses	Expenses	Expenses	Expenses	Total
1.	Rent (\$0 for occupancy of				_	
	own building)					
2.	Salary, wages and other benefits	43,872,939	29,951,052	119,780,624	0	193,604,615
3.	Commissions (less \$0					
	ceded plus \$0 assumed)					
4.	Legal fees and expenses			1,146,093		
5.	Certifications and accreditation fees			0		
6.	Auditing, actuarial and other consulting services					
7.	Traveling expenses			3,988,438		
8.	Marketing and advertising		1,966,781		0	
9.	Postage, express and telephone		1,941,969	7,766,349		
10.	Printing and office supplies	833 , 193	568,802	2,274,761	0	3,676,756
11.	Occupancy, depreciation and amortization	935,248	638,473	2,553,388	0	4 , 127 , 109
12.	Equipment	169,141	115,469	461,784	0	746,394
13.	Cost or depreciation of EDP equipment and software	5,426,776	3,704,736	14,816,028	0	23,947,540
14.	Outsourced services including EDP, claims, and other services	8,934,448	4,630,881	15,519,749	0	29,085,078
15.	Boards, bureaus and association fees	76,213	52,029	208,076	0	336,318
16.	Insurance, except on real estate	728,555	497,368	1,989,079	0	3,215,002
17.	Collection and bank service charges		194,904	779,464	0	1,259,868
18.	Group service and administration fees		830,044	3,318,032	0	5,363,942
19.	Reimbursements by uninsured plans		0	0	0	L0
20.	Reimbursements from fiscal intermediaries		0	0	0	Lo
21.	Real estate expenses		0	0		
22.	Real estate taxes		43,686		0	598,791
23.	Taxes, licenses and fees:		10,000			
20.	23.1 State and local insurance taxes	0	0	301,991	0	301,991
	23.2 State premium taxes			46		· · · · · · · · · · · · · · · · · · ·
	23.3 Regulatory authority licenses and fees					
	23.4 Payroll taxes		0	00,930,023	0	00,930,023
	23.5 Other (excluding federal income and real					
	estate taxes)		0		0	0
24.	Investment expenses not included elsewhere		0	0	384,263	384,263
25.	Aggregate write-ins for expenses		3,102,466	14,567,841	0	22,214,864
26.	Total expenses incurred (Lines 1 to 25)		54,659,980	338,570,400		, ,
27.	Less expenses unpaid December 31, current year		1,908,313	4,381,497		9,249,551
28. 29.	Add expenses unpaid December 31, prior year Amounts receivable relating to uninsured plans,		1,517,960	7,486,882	99 , 153	11,141,648
30.	prior year	0	0	0	0	0
	current year	0	0	0	0	0
31.	minus 29 plus 30)	81,472,486	54,269,627	341,675,785	397,262	477,815,160
	DETAILS OF WRITE-INS					
2501.	Information Technology	•	339,985	1,359,673		ĺ
2502.	Interest		14,495		0	532,798
2503.	Managed Care & Network Access	34 , 178	23,333	93,312	0	150,823
2598.	Summary of remaining write-ins for Line 25 from overflow page	3,991,129	2,724,653	12,617,785	0	19,333,567
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	4,544,557	3,102,466	14,567,841	0	22,214,864
a) Inclu	des management fees of \$249,441,135 to	affiliates and \$	0 to no	n-affiliates.	·	·

(a) Includes management fees of \$ _____249,441,135 to affiliates and \$ _____0 to non-affiliates.

EXHIBIT OF NET INVESTMENT INCOME

		1 Collected During Year	2 Formed During Voor
1.	U.S. government bonds		
1.1	Bonds exempt from U.S. tax		
1.2	Other bonds (unaffiliated)		
1.3	Bonds of affiliates	* *	
2.1	Preferred stocks (unaffiliated)		0
2.11	Preferred stocks of affiliates	(b) 0	
2.2	Common stocks (unaffiliated)	` '	
2.21	Common stocks of affiliates	0	0
3.	Mortgage loans		
4.	Real estate		
5	Contract Loans	0	0
6	Cash, cash equivalents and short-term investments	(e) 31 805	31 805
7	Derivative instruments	(f) 0	0
8.	Other invested assets		0
9.	Aggregate write-ins for investment income	0	0
10.	Total gross investment income	10,701,577	
11.	Investment expenses		(a) 384.263
12.	Investment taxes, licenses and fees, excluding federal income taxes		
13.	Interest expense		
14.	Depreciation on real estate and other invested assets		
15.	Aggregate write-ins for deductions from investment income		
16.	Total deductions (Lines 11 through 15)		384,255
17.	Net investment income (Line 10 minus Line 16)		9,345,562
	DETAILS OF WRITE-INS		
0901.			
0902.			
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0
(a) Inclu	des \$370,420 accrual of discount less \$7,046,439 amortization of premium and less \$607,8	59 paid for accrued int	erest on purchases.
(b) Inclu	des \$0 accrual of discount less \$	0 paid for accrued div	vidends on purchases.
(c) Inclu	des \$0 accrual of discount less \$0 amortization of premium and less \$	0 paid for accrued int	erest on purchases.
(d) Inclu	des \$0 for company's occupancy of its own buildings; and excludes \$	ncumbrances.	
(e) Inclu	des \$0 accrual of discount less \$	0 paid for accrued int	erest on purchases.

EXHIBIT OF CAPITAL GAINS (LOSSES)

____0 investment expenses and \$ ______0 investment taxes, licenses and fees, excluding federal income taxes, attributable to

 $(f) \ Includes \$ \qquad 0 \ \ accrual \ of \ discount \ less \$ \ 0 \ \ amortization \ of \ premium.$

(i) Includes \$ _____0 depreciation on real estate and \$ _____0 depreciation on other invested assets.

segregated and Separate Accounts.

	EMINDII	1	2	3	4	5
		1	2	3	7	3
İ						
				Total Realized Capital		Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	1,507,450	0	1,507,450	0	0
1.1	Bonds exempt from U.S. tax	0	0	0	0	0
1.2	Other bonds (unaffiliated)	1,153,85/	0	1, 153, 857	0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate	0	0	0	0	0
5.	Contract loans	0	0	0	0	0
6.	Cash, cash equivalents and short-term investments	0	0	0	0	0
7.	Derivative instruments	0	0	0	0	0
8.	Other invested assets	0	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	2,661,307	0	2,661,307	0	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,	0	0	0	0	

EXHIBIT OF NON-ADMITTED ASSETS

	EXHIBIT OF NON-ADMITTE	1	2	3
		Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)	_	0	0
	Stocks (Schedule D):			
	2.1 Preferred stocks	0	0	0
	2.2 Common stocks	_		0
3.	Mortgage loans on real estate (Schedule B):			
0.	3.1 First liens	0	0	0
	3.2 Other than first liens.			
4.	Real estate (Schedule A):			
	4.1 Properties occupied by the company	0	0	0
	4.2 Properties held for the production of income.			
	4.3 Properties held for sale			
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments			
0.	(Schedule DA)	0	0	0
6.	Contract loans	0	0	0
7.	Derivatives (Schedule DB)	0	0	0
8.	Other invested assets (Schedule BA)	0	0	0
9.	Receivables for securities	0	0	0
10.	Securities lending reinvested collateral assets (Schedule DL)	0	0	0
11.	Aggregate write-ins for invested assets	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	0	0	0
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued	0	0	0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection	6,341,281	3,270,958	(3,070,323)
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
	15.3 Accrued retrospective premiums and contracts subject to redetermination			
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers	0	0	0
	16.2 Funds held by or deposited with reinsured companies	0	0	0
	16.3 Other amounts receivable under reinsurance contracts			
17.	Amounts receivable relating to uninsured plans			
	Current federal and foreign income tax recoverable and interest thereon		0	0
	Net deferred tax asset	_	0	0
19.	Guaranty funds receivable or on deposit	0	0	0
20.	Electronic data processing equipment and software		0	0
21.	Furniture and equipment, including health care delivery assets		0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates		0	0
23.	Receivable from parent, subsidiaries and affiliates	_	0	0
24.	Health care and other amounts receivable		42,582,704	(6, 175, 281)
25.	Aggregate write-ins for other than invested assets		0	(1,009)
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)		46,027,899	(9,262,484)
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0
28.	Total (Lines 26 and 27)	55,290,383	46,027,899	(9,262,484)
	DETAILS OF WRITE-INS			
1101.				
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Miscellaneous Receivables	1,009	0	(1,009)
2502.				
2503.				
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	1,009	0	(1,009)

17

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

				Total Members at End of			6
		1	2	3	4	5	Current Year
	Source of Enrollment	Prior Year	First Quarter	Second Quarter	Third Quarter	Current Year	Member Months
1.	Health Maintenance Organizations	0	0	0	0	0	0
2.	Provider Service Organizations	0	0	0	0	0	0
3.	Preferred Provider Organizations	259,608	262,227	266,067	270,615	273,800	3,205,644
4.	Point of Service	0	0	0	0	0	0
5.	Indemnity Only	4	4	4	4	4	48
6.	Aggregate write-ins for other lines of business.	0	0	0	0	0	0
7.	Total	259,612	262,231	266,071	270,619	273,804	3,205,692
	DETAILS OF WRITE-INS						
0601.							
0602.							
0603.							
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

CARE IMPROVEMENT PLUS SOUTH CENTRAL INSURANCE COMPANY

NOTES TO STATUTORY BASIS FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2016 AND 2015

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN

Organization and Operation

Care Improvement Plus South Central Insurance Company (the "Company"), licensed as an accident, and health insurer (limited to Medicare only products), offers its enrollees a variety of managed care programs and products through contractual arrangements with health care providers. The Company is a wholly owned subsidiary of XLHealth Corporation ("XLHealth"). XLHealth is a wholly owned subsidiary of United HealthCare Services, Inc. ("UHS"), a health maintenance organization ("HMO"), management corporation that provides services to the Company under the terms of a management agreement (the "Agreement"). UHS is a wholly owned subsidiary of UnitedHealth Group Incorporated ("UnitedHealth Group"). UnitedHealth Group is a publicly held company trading on the New York Stock Exchange.

The Company was incorporated on January 13, 2006, as an accident and health insurer (limited to Medicare only products) in Arkansas and operations commenced in January 2007. The Company is certified as an accident and health insurer in 25 states. The Company has entered into contracts with physicians, hospitals, and other health care provider organizations to deliver health care services for all enrollees.

The Company serves as a plan sponsor offering Medicare Advantage and Medicare Part D prescription drug insurance coverage (collectively "Medicare program") under a contract with the Centers for Medicare and Medicaid Services ("CMS"). Under the Medicare program, there are seven separate elements of payment received by the Company either during the year or at settlement in the subsequent year. These payment elements are CMS premium, member premium, CMS low-income premium subsidy, CMS catastrophic reinsurance subsidy, CMS low-income member cost-sharing subsidy, CMS risk share, and the CMS coverage gap discount program ("CGDP"). Each component of the Medicare program is further defined throughout Note 1.

A. Accounting Practices

The statutory basis financial statements of the Company are presented on the basis of accounting practices prescribed and permitted by the Arkansas Insurance Department (the "Department").

The Department recognizes only statutory accounting practices, prescribed and permitted by the State of Arkansas, for determining and reporting the financial condition and results of operations of a life, accident, and health insurer, for determining its solvency under Arkansas Insurance Law. The state prescribes the use of the National Association of Insurance Commissioners' ("NAIC") Accounting Practices and Procedures manual ("NAIC SAP") in effect for the accounting periods covered in the statutory basis financial statements.

No significant differences exist between the practices prescribed and permitted by the State of Arkansas and those prescribed and permitted by the NAIC SAP which materially affect the statutory basis net income and capital and surplus, as illustrated in the table below:

	SSAP#	F/S Page #	F/S Line #	2016	2015
Net Income (Loss)					
(1) Company state basis(2) State prescribed practices that increase/(decrease) NAIC SAP: None	XXX	XXX	xxx	\$ 241,424,946	\$ 35,337,296
(3) State permitted practices that increase/(decrease) NAIC SAP: None					
(4) NAIC SAP (1 - 2 - 3 = 4)	XXX	XXX	XXX	\$ 241,424,946	\$ 35,337,296
Capital and Surplus					
(5) Company state basis (Page 3, Line 38, Columns 1 & 2)(6) State prescribed practices that increase/(decrease) NAIC SAP: None	xxx	xxx	x xx	\$ 423,064,238 	\$315,151,737
(7) State permitted practices that increase/(decrease) NAIC SAP: None					
(8) NAIC SAP (5 - 6 - 7 = 8)	XXX	XXX	XXX	\$ 423,064,238	\$315,151,737

B. Use of Estimates in the Preparation of the Statutory Basis Financial Statements

The preparation of these statutory basis financial statements in conformity with the NAIC Annual Statement Instructions and the NAIC SAP include certain amounts that are based on the Company's estimates and judgments. These estimates require the Company to apply complex assumptions and judgments, often because the Company must make estimates about the effects of matters that are inherently uncertain and will change in subsequent periods. The most significant estimates relate to hospital and medical benefits, claims unpaid, aggregate health policy reserves and aggregate health claim reserves. The Company adjusts these estimates each period as more current information becomes available. The impact of any changes in estimates is included in the determination of net income in the period in which the estimate is adjusted.

C. Accounting Policy

Basis of Presentation — The Company prepares its statutory basis financial statements on the basis of accounting practices prescribed and permitted by the Department. These statutory practices differ from accounting principles generally accepted in the United States of America ("GAAP").

Accounting policy disclosures that are required by the NAIC Annual Statement instructions are as follows:

- (1–2) Bonds and short-term investments are stated at amortized cost if they meet NAIC designation of one or two and stated at the lower of amortized cost or fair value if they meet an NAIC designation of three or higher. Amortization of bond premium or accretion of discount is calculated using the constant-yield interest method. Bonds and short-term investments are valued and reported using market prices published by the Securities Valuation Office of the NAIC ("SVO") in accordance with the NAIC Valuations of Securities manual prepared by the SVO or an external pricing service;
- (3-4) The Company holds no common or preferred stock;
- (5) The Company holds no mortgage loans on real estate;
- (6) U.S. government and agency securities and corporate debt securities include loan-backed securities (mortgage-backed securities and asset-backed securities), which are valued using the retrospective adjustment methodology. Prepayment assumptions for the determination of the amortized cost of loan-backed securities are based on a three-month constant prepayment rate history obtained from external data source vendors. The Company's investment policy limits investments in nonagency residential mortgage-backed securities, including home equity and sub-prime mortgages, to 10% of total cash and invested assets. Total combined investments in mortgage-backed securities and asset-backed securities cannot exceed more than 30% of total cash and invested assets;
- (7) The Company holds no investments in subsidiaries, controlled, or affiliated entities;
- (8) The Company has no investment interests with respect to joint ventures, partnerships, or limited liability companies;
- (9) The Company holds no derivatives;
- Premium deficiency reserves and the related expenses are recognized when it is probable (10)that expected future health care expenses, claims adjustment expenses ("CAE"), direct administration costs, and an allocation of indirect administration costs under a group of existing contracts will exceed anticipated future premiums and reinsurance recoveries considered over the remaining lives of the contracts, and are recorded as aggregate health policy reserves in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Indirect administration costs arise from activities that are not specifically identifiable to a specific group of existing contracts, and therefore, those costs are fully allocated among the various contract groupings. The allocation of indirect administration costs to each contract grouping is made proportionately to the expected margins remaining in the premiums after future health care expenses, CAE, and direct administration costs are considered. The methods for making such estimates and for establishing the resulting reserves are periodically reviewed and updated, and any adjustments are reflected as an increase or decrease in reserves for life and accident and health contracts in the statutory basis statements of operations in the period in which the change in estimate is identified. The Company anticipates investment income as a factor in the premium deficiency calculation (see Note 30);

- (11) CAE are those costs expected to be incurred in connection with the adjustment and recording of accident and health claims. Pursuant to the terms of the Agreement (see Note 10), the Company pays a management fee to its affiliate, UHS, in exchange for administrative and management services. A detailed review of the administrative expenses of the Company and the service providers is performed to determine the allocation between claims adjustment expenses and general administrative expenses to be reported in the statutory basis statement of operations. It is the responsibility of UHS to pay CAE in the event the Company ceases operations. The Company has recorded an estimate of unpaid CAE associated with incurred but unpaid claims, which is included in unpaid claims adjustment expenses in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Management believes the amount of the liability for unpaid CAE as of December 31, 2016 is adequate to cover the Company's cost for the adjustment and recording of unpaid claims; however, actual expenses may differ from those established estimates. Adjustments to the estimates for unpaid CAE are reflected in operating results in the period in which the change in estimate is identified;
- (12) The Company does not carry any fixed assets on the statutory basis financial statements;
- (13) Health care receivables consist of pharmacy rebates receivable estimated based on the most currently available data from the Company's claims processing systems and from data provided by the Company's affiliated pharmaceutical benefit manager, OptumRx, Inc. ("OptumRx"). Health care receivables also include provider recoveries. Provider recoveries consist of claim overpayments to providers which are due back to the Company. Health care receivables are considered nonadmitted assets under NAIC SAP if they do not meet admissibility requirements. Accordingly, the Company has excluded receivables that do not meet the admissibility criteria from the statutory basis statements of admitted assets, liabilities, and capital and surplus (see Note 28).

The Company has also deemed the following to be significant accounting policies and/or differences between statutory practices and GAAP:

ASSETS

Cash and Invested Assets

- Bonds include U.S. government and agency securities, corporate debt securities, state
 municipal securities, and political subdivision municipal securities, with a maturity of greater
 than one year at the time of purchase;
- Certain debt investments categorized as available-for-sale or held-to-maturity under GAAP
 are presented at the lower of amortized cost or fair value in accordance with the NAIC in
 the statutory basis financial statements, whereas under GAAP, these investments are
 shown at fair value or amortized cost, respectively;
- Cash, cash overdrafts, and short-term investments in the statutory basis financial statements represent cash balances and investments with original maturities of one year or less from the time of acquisition, whereas under GAAP, the corresponding caption of cash, cash equivalents, and short-term investments includes cash balances and investments that will mature in one year or less from the balance sheet date;
- Cash represents cash held by the Company in disbursement accounts. Claims and other
 payments are made from the disbursement accounts daily. Cash overdrafts are a result of
 timing differences in funding disbursement accounts for claims payments;
- Outstanding checks are required to be netted against cash balances or presented as cash overdrafts if in excess of cash balances in the statutory basis statements of admitted assets, liabilities, and capital and surplus as opposed to being presented as other liabilities under GAAP;
- Short-term investments represent money market instruments with a maturity of greater than three months but less than one year at the time of purchase;
- Realized capital gains and losses on sales of investments are calculated based upon specific identification of the investments sold. These gains and losses are reported as net realized capital gains less capital gains tax in the statutory basis statements of operations;

- The Company continually monitors the difference between amortized cost and estimated fair value of its investments. If any of the Company's investments experience a decline in value that the Company has determined is other-than-temporary, or if the Company has determined it will sell a security that is in an impaired status, the Company will record a realized loss in capital gains less capital gains tax in the statutory basis statements of operations. The new cost basis is not changed for subsequent recoveries in fair value. The prospective adjustment method is utilized for loan-backed securities for periods subsequent to the loss recognition. The Company recognized an other-than-temporary impairment ("OTTI") of \$0 and \$321,495 for the years ended December 31, 2016 and 2015, respectively;
- The statutory basis statements of cash flows reconcile cash, cash overdrafts and short-term investments with original maturities of one year or less from the time of acquisition; whereas under GAAP, the statements of cash flows reconcile the corresponding captions of cash and cash equivalents with maturities of three months or less. Short-term investments with a final maturity of one year or less from the balance sheet date are not included in the reconciliation of GAAP cash flows. In addition, there are classification differences within the presentation of the cash flow categories between GAAP and statutory reporting. The statutory basis statements of cash flows are prepared in accordance with the NAIC Annual Statement Instructions.

Other Assets

- Investment Income Due and Accrued Investment income earned and due as of the reporting date, in addition to investment income earned but not paid or collected until subsequent periods, is reported as investment income due and accrued in the statutory basis statements of admitted assets, liabilities, and capital and surplus. The Company evaluates the collectability of the amounts due and accrued and amounts determined to be uncollectible are written off in the period in which the determination is made. In addition, the remaining balance is assessed for admissibility and any balance greater than 90 days past due is considered a nonadmitted asset.
- Premiums and Considerations The Company reports uncollected premium balances from its insured members as premiums and considerations in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Uncollected premium balances that are over 90 days past due, with the exception of amounts due from government insured plans, are considered nonadmitted assets. In addition to those balances, current balances are also considered nonadmitted if the corresponding balance greater than 90 days past due is deemed more than inconsequential. Premiums and considerations also include CMS risk adjustment receivables. The risk adjustment model apportions premiums paid to all health plans according to the health severity and certain demographic factors of its enrollees. The CMS risk adjustment model pays more for members whose medical history indicates they have certain medical conditions. Under this risk adjustment methodology, CMS calculates the risk-adjusted premium payment using diagnosis data from hospital inpatient, hospital outpatient, and physician treatment settings. The Company and health care providers collect, capture, and submit the necessary and available diagnosis data to CMS within prescribed deadlines. The Company estimates risk adjustment revenues based upon the diagnosis data submitted and expected to be submitted to CMS. The Company recognizes such changes when the amounts become determinable and supportable and collectability is reasonably assured.
- Amounts Receivable Relating to Uninsured Plans Receivables for amounts held under uninsured plans represent the costs incurred in excess of the cost reimbursement under the Medicare program for the catastrophic reinsurance subsidy and the low-income member cost-sharing subsidy for the individual members. The Company is fully reimbursed by CMS for costs incurred for these contract elements, and accordingly, there is no insurance risk to the Company. Amounts received for these subsidies are received monthly and are not reflected as net premium income, but rather are accounted for as deposits. If the Company incurs costs in excess of these subsidies, a corresponding receivable is recorded in amounts receivable relating to uninsured plans in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Related cash flows are presented within operating expenses paid within net cash provided by operations in the statutory basis statements of cash flows. The Patient Protection and Affordable Care Act and its related legislation ("ACA") mandates consumer discounts of 50% on brand name prescription drugs for Part D plan participants in the coverage gap. As part of the CGDP, the Company records a receivable from the pharmaceutical manufacturers for reimbursement of the discounts which is included in amounts receivable relating to uninsured plans in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Related cash flows are presented within operating expenses paid within net cash provided by operations in the statutory basis statements of cash flows. The Company solely administers the application of these funds and has no insurance risk.

- Current Federal Income Tax Recoverable The Company is included in the consolidated federal income tax return with its ultimate parent, UnitedHealth Group under which taxes approximate the amount that would have been computed on a separate company basis, with the exception of net operating losses and capital losses. For these losses, the Company receives a benefit at the federal rate in the current year for current taxable losses incurred in that year to the extent losses can be utilized in the consolidated federal income tax return of UnitedHealth Group. A current federal income tax recoverable is recognized when the Company's allocated intercompany estimated payments are more than its actual calculated obligation based on the Company's stand-alone federal income tax return (see Note 9).
- Net Deferred Tax Asset NAIC SAP provides for an amount to be recorded for deferred taxes on temporary differences between the financial reporting and tax bases of assets, subject to a valuation allowance and admissibility limitations on deferred tax assets (see Note 9). In addition, under NAIC SAP, the change in deferred tax assets is recorded directly to unassigned surplus in the statutory basis financial statements, whereas under GAAP, the change in deferred tax assets is recorded as a component of the income tax provision within the income statement and is based on the ultimate recoverability of the deferred tax assets. Based on the admissibility criteria under NAIC SAP, any deferred tax assets determined to be nonadmitted are charged directly to surplus and excluded from the statutory basis financial statements, whereas under GAAP, such assets are included in the balance sheet.

LIABILITIES

• Claims Unpaid and Aggregate Health Claim Reserves — Claims unpaid and aggregate health claim reserves include claims processed but not yet paid, estimates for claims received but not yet processed, estimates for the costs of health care services enrollees have received but for which claims have not yet been submitted, and payments and liabilities for physician, hospital, and other medical costs disputes.

The estimates for incurred but not yet reported claims are developed using an actuarial process that is consistently applied, centrally controlled, and automated. The actuarial models consider factors such as historical submission and payment data, cost trends, customer and product mix, seasonality, utilization of health care services, contracted service rates, and other relevant factors. The Company estimates such liabilities for physician, hospital, and other medical cost disputes based upon an analysis of potential outcomes, assuming a combination of litigation and settlement strategies. These estimates may change as actuarial methods change or as underlying facts upon which estimates are based change. The Company did not change actuarial methods during 2016 and 2015. Management believes the amount of claims unpaid and aggregate health claim reserves is a best estimate of the Company's liability for unpaid health claims and aggregate health claim reserves as of December 31, 2016; however, actual payments may differ from those established estimates.

The Company contracts with hospitals, physicians, and other providers of health care under capitated or discounted fee for service arrangements, including a hospital per diem to provide medical care services to enrollees. Some of these contracts are with related parties (see Note 10). Capitated providers are at risk for the cost of medical care services provided to the Company's enrollees; however, the Company is ultimately responsible for the provision of services to its enrollees should the capitated provider be unable to provide the contracted services.

- Accrued Medical Incentive Pool and Bonus Amounts The Company has agreements with certain independent physicians and physician network organizations that provide for the establishment of a fund into which the Company places monthly premiums payable for members assigned to the physician. The Company manages the disbursement of funds from this account as well as reviews the utilization of nonprimary care medical services of members assigned to the physicians. Any surpluses in the fund are shared by the Company and the physician based upon predetermined risk-sharing percentage and the liability is included in accrued medical incentive pool and bonus amounts in the statutory basis statements of admitted assets, liabilities, and capital and surplus.
- Aggregate Health Policy Reserves Aggregate health policy reserves includes CMS risk corridor payables for which adjustments are based on whether the ultimate per member per month ("PMPM") benefit costs of any Medicare Part D program plan varies more than 5% below the level estimated in the original bid submitted by the Company and approved by CMS (see Note 24).
- **Premiums Received in Advance** Premiums received in full during the current period that are not due until future periods are recorded as premiums received in advance in the statutory basis statements of admitted assets, liabilities, and capital and surplus.

- General Expenses Due or Accrued General expenses that are due as of the reporting
 date in addition to general expenses that have been incurred but are not due until a
 subsequent period are reported as general expenses due or accrued in the statutory basis
 statements of admitted assets, liabilities, and capital and surplus. General expenses due or
 accrued also include the amounts for unpaid assessments and state income taxes.
- Remittances and Items Not Allocated Remittances and items not allocated generally
 represent monies received from policyholders for monthly premium billings or providers that
 have not been specifically identified or applied prior to year-end. The majority is from
 monies received in the lockbox account on the last day of the year.
- Amounts Due to Parent, Subsidiaries, and Affiliates, Net In the normal course of business, the Company has various transactions with related parties (see Note 10). The Company reports any unsettled amounts owed as amounts due to parent, subsidiaries, and affiliates, net, in the statutory basis statements of admitted assets, liabilities, and capital and surplus.
- Liability for Amounts Held Under Uninsured Plans Liability for amounts held under uninsured plans represents costs incurred that are associated with the gap coverage discount program. The ACA mandates consumer discounts of 50% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are pre-funded for the members by CMS and a liability for the amount subject to recoupment is recorded in liability for amounts held under uninsured plans in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Related cash flows are presented within operating expenses paid within net cash provided by operations in the statutory basis statements of cash flows. The Company solely administers the application of these funds and has no insurance risk.

CAPITAL AND SURPLUS AND MINIMUM STATUTORY REQUIREMENTS

- Nonadmitted Assets Certain assets, including certain aged premium receivables, amounts receivable relating to uninsured plans, and certain health care receivables are considered nonadmitted assets under NAIC SAP and are excluded from the statutory basis statements of admitted assets, liabilities, and capital and surplus and charged directly to unassigned surplus. Under GAAP, such assets are included in the balance sheet.
- Restricted Cash Reserves The Company held regulatory deposits in the amount of \$4,079,018 and \$4,222,981 as of December 31, 2016 and 2015, respectively, in compliance with the various states requirements for qualification purposes as a domestic and foreign insurer. These restricted cash reserves consist principally of government obligations and are stated at amortized cost, which approximates fair value. These restricted deposits are included in bonds and short-term investments in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Interest earned on these deposits accrues to the Company.
- Minimum Capital and Surplus Under the laws of the State of Arkansas, the Department requires the Company to maintain a minimum capital and surplus equal to the greater of \$100,000 for the benefit of all policyholders and creditors in Arkansas or the company action level Risk-Based Capital ("RBC") per the NAIC's RBC calculation. The minimum capital and surplus requirement was \$229,163,128 and \$196,204,818, for December 31, 2016 and 2015, respectively, which was based on RBC, as that produced the highest minimum requirement. The Company is in compliance with the required amount.

RBC is a regulatory tool for measuring the minimum amount of capital appropriate for a managed care organization to support its overall business operations in consideration of its size and risk profile. The Department requires the Company to maintain minimum capital and surplus equal to the greater of the state statute as outlined above, or the company action level as calculated by the RBC formula or the level needed to avoid action pursuant to the trend test in the RBC formula. The Company is in compliance with the required amount.

Section 9010 ACA Subsequent Fee Year Assessment — In 2016 and 2015, the Company is subject to the Section 9010 ACA Health Insurer Fee ("HIF"). In accordance with the 2017 HIF moratorium, no HIF will be payable in 2017 and therefore the 2016 statutory basis statements of admitted assets, liabilities, and capital and surplus will have no amounts apportioned out of unassigned funds representing an estimate of the 2017 HIF. In 2015, under NAIC SAP, an amount equal to the estimated subsequent year fee was apportioned out of unassigned surplus and reported as Section 9010 ACA subsequent fee year assessment in the statutory basis statements of admitted assets, liabilities, and capital and surplus, whereas under GAAP, no such special surplus designation is required.

STATEMENTS OF OPERATIONS

Net Premium Income and Change in Unearned Premium Reserves and Reserve for Rate Credits — Revenues consist of net premium income that is recognized in the period in which enrollees are entitled to receive health care services. Net premium income is shown net of reinsurance premiums paid and reinsurance premiums incurred but not paid in the statutory basis statements of operations. The corresponding change in unearned premium from year to year is reflected as a change in unearned premium reserves and reserve for rate credits in the statutory basis statements of operations. Under GAAP, the change in unearned premium from year to year is reported through premium income.

Net premium income includes premium under the Medicare Advantage program, which includes CMS premium and member premium. It also includes premium under the Medicare program, which includes CMS premium, member premium, and CMS low-income premium subsidy for the Company's insurance risk coverage. Net premium income is recognized ratably over the period in which eligible individuals are entitled to receive health care services and prescription drug benefits.

Net premium income also includes amounts pursuant to the CMS risk adjustment program. The Company recognized \$38,079,770 and \$8,934,922 for changes in prior year Medicare risk factor estimates during the years ended December 31, 2016 and 2015, respectively, which is recorded as net premium income in the statutory basis statements of operations.

The Company also records estimates related to the CMS risk corridor program. Changes to these estimates are reflected as change in unearned premium reserves and reserve for rate credits in the statutory basis statements of operations.

Medicare Advantage plans and Part D prescription drug plans are subject to medical loss ratio requirements under the ACA. Plans with medical loss ratios that fall below certain targets are required to rebate ratable portions of premiums annually. The Company classifies its estimated rebates as change in unearned premium reserves and reserve for rate credits in the statutory basis statements of operations.

 Total Hospital and Medical Expenses — Total hospital and medical expenses include claims paid, claims processed but not yet paid, estimates for claims received but not yet processed, estimates for the costs of health care services enrollees have received but for which claims have not yet been submitted, and payments and liabilities for physician, hospital, and other medical costs disputes.

Total hospital and medical expenses also include amounts incurred for incentive pool, withhold adjustments, and bonus amounts that are based on the underlying contractual provisions with the respective providers. In addition, adjustments to claims unpaid estimates and are reflected in the period once the change in estimate is identified and included in total hospital and medical expenses in the statutory basis statements of operations.

• General Administrative Expenses — Pursuant to the terms of the Agreement (see Note 10), the Company pays a management fee to UHS in exchange for administrative and management services. Costs for items not included within the scope of the Agreement are directly expensed as incurred. State income taxes are also a component of general administrative expenses. A detailed review of the administrative expenses of the Company and UHS is performed to determine the allocation between claims adjustment expenses and general administrative expenses to be reported in the statutory basis statements of operations.

The Company is subject to an annual fee under Section 9010 of the ACA. A health insurance entity's annual fee becomes payable once the entity provides health insurance for any U.S. health risk during the calendar year, which is nondeductible for tax purposes. Under NAIC SAP, the entire amount of the estimated annual fee expense is recognized on January 1 of the fee year in general administrative expenses in the statutory basis statements of operations, whereas under GAAP, a deferred asset is created on January 1 of the fee year which is amortized to expense on a straight-line basis throughout the year.

- **Net Investment Income Earned** Net investment income earned includes investment income collected during the period, as well as the change in investment income due and accrued on the Company's holdings. Amortization of premium or discount on bonds and certain external investment management costs are also included in net investment income earned (see Note 7).
- Federal Income Taxes Incurred —The provision for federal income taxes incurred is calculated based on applying the statutory federal income tax rate of 35% to net gain from operations before federal income taxes and net realized capital gains subject to certain adjustments (see Note 9).

 Comprehensive Income — Comprehensive income and its components are not separately presented in the statutory basis financial statements, whereas under GAAP, it is a requirement to present comprehensive income and its components in the financial statements.

REINSURANCE

- Reinsurance Ceded In the normal course of business, the Company seeks to limit its exposure to loss on any single insured and to recover a portion of benefits paid by ceding premium to other insurance enterprises or reinsurers under excess coverage contracts or specific transfer of risk agreements. The Company remains primarily liable as the direct insurer on the risks reinsured. Reinsurance premiums paid and reinsurance premiums incurred but not paid are deducted from net premium income in the statutory basis statements of operations. Any amounts due to the Company pursuant to this agreement are recorded as amounts recoverable from reinsurers in the statutory basis statements of admitted assets, liabilities, and capital and surplus (see Note 10 and Note 23).
- Amounts Recoverable from Reinsurers The Company records amounts recoverable from reinsurers for claims paid pursuant to the reinsurance agreement with Unimerica Insurance Company ("Unimerica") in the statutory basis statements of admitted assets, liabilities, and capital and surplus and as net reinsurance recoveries in the statutory basis statements of operations.
- Ceded Reinsurance Premiums Payable —The ceded reinsurance premiums payable balance represents amounts due to the reinsurer for specified coverage which will be paid based on the contract terms.

OTHER

• Vulnerability Due to Certain Concentrations — The Company is subject to substantial federal and state government regulation, including licensing and other requirements relating to the offering of the Company's existing products in new markets and offerings of new products, both of which may restrict the Company's ability to expand its business.

Direct premiums written and uncollected premiums, including risk adjustment factor receivables, from members and CMS related to Medicare Advantage and the Medicare Part D program as a percentage of total direct premiums written and total uncollected premiums, including risk adjustment factor receivables, are 100% as of December 31, 2016 and 2015, respectively.

Recently Issued Accounting Standards — The Company reviewed all recently issued guidance in 2016 and 2015 that has been adopted for 2016 or subsequent years' implementation and has determined that none of the items would have a significant impact to the statutory basis financial statements.

D. Going Concern

The Company has the ability and will continue to operate for a period of time sufficient to carry out its commitments, obligations and business objectives.

2. ACCOUNTING CHANGES AND CORRECTION OF ERRORS

No changes in accounting principles have been recorded during the years ended December 31, 2016 and 2015

During 2015, the Company determined that it had overstated general and administrative expenses related to the calculation of management fees by \$33,851,626 for the year ended December 31, 2014. In addition, the federal income taxes benefit and state income taxes expense as a result of this error was understated by \$11,843,737 and \$12,377, respectively, for the year ended December 31, 2014. Had the above adjustment been recorded to the 2014 statutory basis financial statements, the increase (decrease) to net income, total capital and surplus, total assets and total liabilities would have been \$21,995,512, \$21,995,512, (\$11,856,114), and (\$33,851,626), respectively. Due to the significance of the error, the cumulative effect of this prior year error was corrected by the Company in accordance with Statements of Statutory Accounting Principles ("SSAP") No. 3, Accounting Changes and Corrections of Errors, and is reflected in the statutory basis statements of changes in capital and surplus as a SSAP No. 3 correction of prior year error for the year ended December 31, 2016.

3. BUSINESS COMBINATIONS AND GOODWILL

A–D. The Company was not party to a business combination during the years ended December 31, 2016 and 2015, and does not carry goodwill in its statutory basis statements of admitted assets, liabilities, and capital and surplus.

4. DISCONTINUED OPERATIONS

- A. Discontinued Operation Disposed of or Classified as Held for Sale
- (1–4) The Company did not have any discontinued operations disposed of or classified as held for sale during 2016 and 2015.
- B. Change in Plan of Sale of Discontinued Operation Not applicable.
- C. Nature of any Significant Continuing Involvement with Discontinued Operations after Disposal Not applicable.
- D. Equity Interest Retained in the Discontinued Operation after Disposal Not applicable.

5. INVESTMENTS AND OTHER INVESTED ASSETS

For purposes of calculating gross realized gains and losses on sales of investments, the amortized cost of each investment sold is used. The gross realized gains and losses on sales of long-term investments were \$3,300,790 and \$639,483, respectively, for 2016 and \$3,267,530 and \$65,391, respectively, for 2015. The Company did not have any gross realized gains and losses on sales of short-term investments for 2016 and 2015. The net realized gain is included in net realized capital gains less capital gains tax in the statutory basis statements of operations. Total proceeds on the sale of long-term investments were \$279,520,571 and \$220,058,493 and for short-term investments were \$271,923,326 and \$198,912,583 in 2016 and 2015, respectively.

As of December 31, 2016 and 2015, the amortized cost, fair value, and gross unrealized holding gains and losses of the Company's investments, excluding cash of \$235,128,988 and \$62,377,672, respectively, are as follows:

			2016		
	Amortized Cost	Gross Unrealized Holding Gains	Gross Unrealized Holding Losses < 1 Year	Gross Unrealized Holding Losses > 1 Year	Fair Value
U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities Money-market funds Total bonds and short-term investments	\$ 54,446,628 60,147,620 96,891,099 127,868,529 15,365,292 \$ 354,719,168	\$ 2,950 156,726 286,839 568,452 - \$ 1,014,967	\$ 1,972,445 800,375 1,189,817 517,744 	\$ - - 222,400 - \$ 222,400	\$ 52,477,133 59,503,971 95,988,121 127,696,837 15,365,292 \$ 351,031,354
			0040		
	Amortized Cost	Gross Unrealized Holding Gains	2016 Gross Unrealized Holding Losses < 1 Year	Gross Unrealized Holding Losses > 1 Year	Fair Value
Less than one year One to five years Five to ten years Over ten years	\$ 36,553,479 135,635,762 130,562,470 51,967,457	\$ 18,963 304,529 525,973 165,502	\$ 14,084 720,923 2,964,709 780,665	\$ 2,669 8,434 - 211,297	\$ 36,555,689 135,210,934 128,123,734 51,140,997
Total bonds and short-term investments	\$ 354,719,168	\$ 1,014,967	\$ 4,480,381	\$ 222,400	\$ 351,031,354
			2015		
	Amortized Cost	Gross Unrealized Holding Gains	Gross Unrealized Holding Losses < 1 Year	Gross Unrealized Holding Losses > 1 Year	Fair Value
U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities Money-market funds	\$ 99,137,016 89,884,650 131,647,766 165,078,953 5,839,795	\$ 295,710 1,011,489 1,756,065 308,905	\$ 348,176 50,298 51,344 1,257,145	\$ 3,045 - - 625,279 -	\$ 99,081,505 90,845,841 133,352,487 163,505,434 5,839,795
Total bonds and short-term investments	\$ 491,588,180	\$ 3,372,169	\$1,706,963	\$ 628,324	\$ 492,625,062

Included in U.S. government and agency securities and corporate debt securities in the tables above are mortgage-related loan-backed securities, which do not have a single maturity date. For the years to maturity table above, these securities have been presented in the maturity group based on the securities' final maturity date and at an amortized cost of \$17,569,491 and fair value of \$17,160,989.

The following table illustrates the fair value and gross unrealized holding losses, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position as of December 31, 2016 and 2015:

			2016	
	Fair Value	1 Year Gross Unrealized Holding Losses	>1 Year Gross Unrealized Fair Holding Value Losses	Total Gross Unrealized Fair Holding Value Losses
U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities	\$ 49,603,434 43,384,591 56,259,020 37,939,681	800,375 1,189,817	\$ - \$ - 11,065,954 222,400	\$ 49,603,434 \$ 1,972,445 43,384,591 800,375 56,259,020 1,189,817 49,005,635 740,144
Total bonds an short-term investments	\$ 187,186,726	\$ 4,480,381	<u>\$ 11,065,954</u> <u>\$ 222,400</u>	<u>\$ 198,252,680</u> <u>\$ 4,702,781</u>
	<	1 Year	2015 > 1 Year	Total
	Fair Value	Gross Unrealized Holding Losses	Gross Unrealized Fair Holding Value Losses	Gross Unrealized Fair Holding Value Losses
U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities	\$ 60,088,487 13,898,514 19,231,808 106,459,331	50,298 51,344	\$ 423,452 \$ 3,045 	\$ 60.511,939 \$ 351,221 13,898,514 50,298 19,231,808 51,344 121,211,158 1,882,424
Total bonds and short-term investments	\$ 199,678,140) \$ 1,706,963	\$ 15,175,279 \$ 628,324	\$ 214,853,419 \$ 2,335,287

The unrealized losses on investments in U.S. government and agency securities, state and agency municipal securities, city and county municipal securities, and corporate debt securities at December 31, 2016 and 2015, were mainly caused by interest rate increases and not by unfavorable changes in the credit ratings associated with these securities. The Company evaluates impairment at each reporting period for each of the securities whereby the fair value of the investment is less than its amortized cost. The contractual cash flows of the U.S. government and agency securities are guaranteed either by the U.S. government or an agency of the U.S. government. It is expected that the securities would not be settled at a price less than the cost of the investment, and the Company does not intend to sell the investment until the unrealized loss is fully recovered. The Company evaluated the credit ratings of the municipal, local agency and corporate debt securities, noting whether a significant deterioration since purchase or other factors that may indicate an OTTI, such as the length of time and extent to which fair value has been less than cost, the financial condition, and near-term prospects of the issuer as well as specific events or circumstances that may influence the operations of the issuer and the Company's intent to sell the investment. Additionally, the Company evaluated its intent and ability to retain loanbacked securities for a period of time sufficient to recover the amortized cost. As a result of these reviews, the Company recorded an OTTI of \$0 and \$321,495 as of December 31, 2016 and 2015, respectively, which are included in net realized capital gains less capital gains tax in the statutory basis statements of operations.

A–C. The Company has no mortgage loans, real estate loans, restructured debt, or reverse mortgages. The Company also has no real estate property occupied by the Company, real estate property held for the production of income, or real estate property held for sale.

D. Loan-Backed Securities

- (1) U.S. government and agency securities and corporate debt securities include loan-backed securities, which are valued using the retrospective adjustment methodology. Prepayment assumptions for the determination of the amortized cost of loan-backed securities are based on a three-month constant prepayment rate history obtained from external data source vendors.
- (2) The Company did not recognize any OTTI on loan-backed securities as of December 31, 2016 and 2015.
- (3) The Company did not have any loan-backed securities with an other-than-temporary impairment OTTI to report by CUSIP as of December 31, 2016 or 2015.

(4) The following table illustrates the fair value, gross unrealized losses, and length of time that the loan-backed securities have been in a continuous unrealized loss position as of December 31, 2016 and 2015:

	2016
The aggregate amount of unrealized losses: 1. Less than 12 months 2. 12 months or longer	\$ 414,141 211,297
The aggregate related fair value of securities with unrealized losses: 1. Less than 12 months 2. 12 months or longer	\$ 14,001,744 7,720,235
	2015
The aggregate amount of unrealized losses: 1. Less than 12 months 2. 12 months or longer	\$ 2015 262,595 389,738

- (5) The Company believes that it will collect all principal and interest due on all investments that have an amortized cost in excess of fair value. The unrealized losses as of December 31, 2016 and 2015 were primarily caused by interest rate increases and not by unfavorable changes in the credit ratings associated with these securities.
- E. Repurchase Agreements and/or Securities Lending Transactions Not applicable.
- F. Real Estate Not applicable.
- G. Low-Income Housing Tax Credits Not applicable.
- H. Restricted Assets.
 - (1) Restricted assets, including pledged securities as of December 31, 2016 and 2015, are presented below:

	1	2	3	4	5	6 Gross	7
Restricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted From Current Year	Total Gross (Admitted & Nonadmitted) Restricted From Prior Year	Increase/ (Decrease) (1 Minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	(Admitted & Nonadmitted) Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a. Subject to contractual							
obligation for which							
liability is not shown	\$ -	\$ -	\$ -	\$ -	\$ -	0 %	0 %
 b. Collateral held under 							
security lending							
agreements	-	-	-	-	-	0 %	0 %
 c. Subject to repurchase 							
agreements	-	-	-	-	-	0 %	0 %
d. Subject to reverse							
repurchase agreements	-	-	-	-	-	0 %	0 %
e. Subject to dollar							
repurchase agreements	-	-	-	-	-	0 %	0 %
f. Subject to dollar reverse						0.0/	2.0/
repurchase agreements	-	-	-	-	-	0 %	0 %
g. Placed under option contracts						0 %	0 %
	-	-	-	-	-	0 %	0 %
h. Letter stock or securities restricted as to sale—							
excluding FHLB capital							
stock						0 %	0 %
i. FHLB capital stock	-	-	-	-	-	0 %	0 %
	4.079.018	4.222.981	(4.42.062)	-	4.079.018	0 %	0 %
j. On deposit with statesk. On deposit with other	4,079,018	4,222,981	(143,963)	-	4,079,018	0 %	0 %
regulatory bodies						0 %	0 %
I. Pledged as collateral	-	-	-	-	-	0 %	0 %
to FHLB (including							
assets backing funding							
agreements)	_	_	_	_	_	0 %	0 %
m Pledged as collateral not	_	_	_	_	_	0 70	0 70
captured in other							
categories	_	_	_	_	_	0 %	0 %
n. Other restricted assets	_	_	_	_	_	0 %	0 %
							<u></u>
o. Total restricted assets	\$ 4,079,018	\$ 4,222,981	\$ (143,963)	s -	\$4,079,018	0 %	0 %
5. 15ta. 155 a. 5ta di di di di di	ψ .,570,010	ψ ., <u>L</u> LL,001	\$\(\tau\)\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	<u> </u>	+ 1,515,010	<u>0 70</u>	<u>0 70</u>

⁽a) Column 1 divided by Asset Page, Column 1, Line 28(b) Column 5 divided by Asset Page, Column 3, Line 28

^(2–4) The Company has no assets pledged as collateral not captured in other categories and no other restricted assets as of December 31, 2016 or 2015.

I. Working Capital Finance Investments — Not applicable.

J. Offsetting and Netting of Assets and Liabilities

The Company does not have any offsetting or netting of assets and liabilities as it relates to derivatives, repurchase and reverse repurchase agreements, and securities borrowing and securities lending activities.

K. Structured Notes

The Company does not have any structured notes.

L. 5* Securities

The Company does not have any investments with an NAIC designation of 5* as of December 31, 2016 and 2015.

6. JOINT VENTURES, PARTNERSHIPS, AND LIMITED LIABILITY COMPANIES

A–B. The Company has no investments in joint ventures, partnerships, or limited liability companies that exceed 10% of admitted assets and did not recognize any impairment write-down for its investments in joint ventures, partnerships, and limited liability companies during the statement periods.

7. INVESTMENT INCOME

- **A.** The Company excludes all investment income due and accrued amounts that are over 90 days past due from the statutory basis statements of admitted assets, liabilities, and capital and surplus.
- **B.** There were no investment income amounts excluded from the statutory basis financial statements.

8. DERIVATIVE INSTRUMENTS

A-F. The Company has no derivative instruments.

9. INCOME TAXES

A. Deferred Tax Asset/Liability

(1) The components of the net deferred tax asset at December 31, 2016 and 2015, are as follows:

		:	2016					2015						Change		
	1 Ordinary		2 Capital	3 (Col 1 + 2) Total		4 Ordinary		5 Capital		6 (Col 4 + 5) Total		7 (Col 1 - 4) Ordinary		8 (Col 2 - 5) Capital		9 (Col 7 + 8) Total
(a) Gross deferred tax assets (b) Statutory valuation allowance adjustments	\$ 20,867,582	\$	-	\$ 20,867,582	\$	17,121,863	\$	113,785 113,785	\$	17,235,648 113,785	\$	3,745,719	\$	(113,785) (113,785)	\$	3,631,934 (113,785)
(c) Adjusted gross deferred tax assets (1a - 1b)	20,867,582		-	20,867,582		17,121,863		-		17,121,863		3,745,719		-		3,745,719
(d) Deferred tax assets nonadmitted	 	_		 	_				_		_		_		_	<u>-</u>
(e) Subtotal net admitted deferred tax asset (1c - 1d)	20,867,582		-	20,867,582		17,121,863		-		17,121,863		3,745,719		-		3,745,719
(f) Deferred tax liabilities	 93,980	_	4,111	 98,091	_	106,899	_	_	_	106,899	_	(12,919)	_	4,111	_	(8,808)
(g) Net admitted deferred tax asset/(net deferred tax liability) (1e - 1f)	\$ 20,773,602	\$	(4,111)	\$ 20,769,491	\$	17,014,964	\$	<u>-</u>	\$	17,014,964	\$	3,758,638	\$	(4,111)	\$	3,754,527

(2) The components of the adjusted gross deferred tax assets admissibility calculation under SSAP No. 101, *Income Taxes—A Replacement of SSAP No. 10R and SSAP No. 10*, are as follows:

_		2016			2015			Change	
Admission Calculation Components SSAP No. 101	1 Ordinary	2 Capital	3 (Col 1 + 2) Total	4 Ordinary	5 Capital	6 (Col 4 + 5) Total	7 (Col 1 - 4) Ordinary	8 (Col 2 - 5) Capital	9 (Col 7 + 8) Total
(a) Federal income taxes paid in prior years recoverable through loss carrybacks	\$20,867,582	\$ -	\$ 20,867,582	\$ 17,121,863	\$ -	\$ 17,121,863	\$ 3,745,719	\$ -	\$ 3,745,719
(b) Adjusted gross deferred tax assets expected to be realized (excluding the amount of deferred tax assets from 2(a) above) after application of the threshold limitation. (The lesser of 2(b)1 and 2(b)2 below) 1. Adjusted gross deferred tax assets expected to be realized following the balance sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold	- - - XXX	- - xxx	- 60,344,212	- - - XXX	- - XXX	- - 44,720,516	- - XXX	- - XXX	- - 15.623.696
(c) Adjusted gross deferred tax assets (excluding the amount of deferred tax assets from 2(a) and 2(b) above) offset by gross deterred tax liabilities						<u>-</u>			
(d) Deferred tax assets admitted as the result of application of SSAP No. 10 Total (2(a) + 2(b) + 2(c))	1 \$20,867,582	<u>\$</u>	\$ 20,867,582	\$ 17,121,863	\$	\$ 17,121,863	\$ 3,745,719	<u>\$</u>	\$ 3,745,719

(3) The ratio percentage and adjusted capital and surplus used to determine the recovery period and threshold limitations for the admissibility calculation are presented below:

	2016	2015
(a) Ratio percentage used to determine recovery period and threshold limitation amount	351 %	304 %
(b) Amount of adjusted capital and surplus used to determine recovery period and threshold limitation		
in 2(b)(2) above	\$ 402,294,747	\$ 298,136,773

(4) The impact to the gross deferred tax assets balances as a result of tax-planning strategies as of December 31, 2016 and 2015 is presented below:

	2016		201	5	Change				
Impact of Tax-Planning Strategies	1 Ordinary	2 Capital	3 Ordinary	4 Capital	5 (Col 1 - 3) Ordinary	6 (Col 2 - 4) Capital			
(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets by tax character as a percentage. 1. Adjusted gross DTAs amount from Note 9A1(c) 2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax-planning strategies 3. Net admitted adjusted gross DTAs amount from Note 9A1(e) 4. Percentage of net admitted adjusted	- %	- %	\$ 17,121,863 - % \$ 17,121,863	- %	\$ 3,745,719 - % \$ 3,745,719	6 - %			
gross DTAs by tax character admitted because of the impact of tax-planning strategies	- %	- %	- %	- %	- %	6 - %			
(b) Does the Company's tax-planning strategies include the use of reinsurance?			Yes		No	X			

B. Unrecognized Deferred Tax Liabilities

(1–4) There are no unrecognized deferred tax liabilities for the years ended December 31, 2016 and 2015.

C. Significant Components of Income Taxes

The current federal and foreign income taxes incurred for the years ended December 31, 2016 and 2015 are as follows:

	1	2	3 (Col 1 - 2)
	2016	2015	Change
Current income tax (a) Federal (b) Foreign	\$ 159,784,303 	\$ 47,655,309 	\$ 112,128,994
(c) Subtotal	159,784,303	47,655,309	112,128,994
(d) Federal income tax on net capital gains(e) Utilization of capital loss carryforwards(f) Other	863,000 - -	1,138,651 - -	(275,651) - -
(g) Total federal and foreign income taxes incurred	\$ 160,647,303	\$ 48,793,960	\$ 111,853,343

(2–4) The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2016 and 2015 are as follows:

2 Deferred tax assets:	1 2016	2 2015	3 (Col 1 - 2) Change
 (a) Ordinary: (1) Discounting of unpaid losses (2) Unearned premium reserve (3) Policyholder reserves (4) Investments 	\$ 1,451,834 64,114 - -	\$ 987,636 22,724 -	\$ 464,198 41,390 - -
 (5) Deferred acquisition costs (6) Policyholder dividends accrual (7) Fixed assets (8) Compensation and benefits accrual (9) Pension accrual (10) Receivables—nonadmitted (11) Net operating loss carryforward 	- - - - - 19,351,634	- - - - 16,109,765	3,241,869
(12) Tax credit carry forward (13) Other (including items <5% of total ordinary tax assets)		1,738	(1,738)
(99) Subtotal	20,867,582	17,121,863	3,745,719
(b) Statutory valuation allowance adjustment(c) Nonadmitted			
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	20,867,582	17,121,863	3,745,719
 (e) Capital: (1) Investments (2) Net capital loss carryforward (3) Real estate (4) Other (including items <5% of total capital tax assets) 	- - - -	113,785 - - -	(113,785) - - -
(99) Subtotal	-	113,785	(113,785)
(f) Statutory valuation allowance adjustment (g) Nonadmitted	<u>-</u>	113,785 	(113,785)
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)			
(i) Admitted deferred tax assets (2d + 2h)	20,867,582	17,121,863	3,745,719
3 Deferred tax liabilities: (a) Ordinary: (1) Investments (2) Fixed assets (3) Deferred and uncollected premium (4) Policyholder reserves	88,816 - - - -	104,701 - - - -	(15,885) - - - -
(5) Other (including items <5% of total ordinary tax liabilities)	5,164	2,198	2,966
(99) Subtotal	93,980	106,899	(12,919)
 (b) Capital: (1) Investments (2) Real estate (3) Other (including items <5% of total capital tax liabilities 	4,111 - -	- - -	4,111 - -
(99) Subtotal	4,111		4,111
(c) Deferred tax liabilities (3a99 + 3b99)	98,091	106,899	(8,808)
4 Net deferred tax assets/liabilities (2i - 3c)	\$ 20,769,491	\$ 17,014,964	\$ 3,754,527

The other ordinary deferred tax liability of \$5,164 and \$2,198 consists of premium acquisition expense in 2016 and 2015, respectively.

The Company assessed the potential realization of the gross deferred tax asset and established a valuation allowance of \$0 and \$113,785 to reduce the gross deferred tax asset to \$20,867,582 and \$17,121,863 as of December 31, 2016 and 2015, respectively, which represents the amount of the asset estimated to be recoverable via carryback of losses and reduction of future taxes. The change in the valuation allowance is attributable to the change in timing of deductibility of expenses and/or expectations for future taxable income.

D. The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory federal income tax rate of 35% to net income before federal income taxes incurred, plus capital gains tax. A summarization of the significant items causing this difference as of December 31, 2016 and 2015 is as follows:

	2016	6	2015			
		Effective		Effective		
	Amount	Tax Rate	Amount	Tax Rate		
Tax provision at the federal statutory rate	\$ 140,725,287	35%	\$ 29,445,941	35%		
Tax-exempt interest	(1,250,343)	0%	(1,275,615)	-2%		
Health insurer fee	20,773,399	5%	20,162,646	24%		
Tax effect of nonadmitted assets	(3,241,869)	-1%	(2,597,324)	-3%		
Prior year true-up	4,419	0%	-	0%		
Other	(118,117)	<u>0</u> %	113,785	<u>0</u> %		
Total statutory income taxes	\$ 156,892,776	<u>39</u> %	\$ 45,849,433	<u>54</u> %		
Federal income taxes incurred	\$ 159,784,303	40%	\$ 47,655,309	57%		
Capital gains tax	863,000	0%	1,138,651	1%		
Change in net deferred tax asset	(3,754,527)	- <u>1</u> %	(2,944,527)	- <u>4</u> %		
Total statutory income taxes	\$ 156,892,776	<u>39</u> %	\$ 45,849,433	<u>54</u> %		

E. At December 31, 2016, the Company had no net operating loss carryforwards.

Current federal income taxes recoverable of \$4,653,117 and \$2,692,040 as of December 31, 2016 and 2015, respectively, are included in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Federal income taxes paid, net of refunds were \$174,452,117 and \$35,352,476 in 2016 and 2015, respectively.

Federal income taxes incurred of \$160,642,884 and \$60,642,117 for 2016 and 2015, respectively, are available for recoupment in the event of future net losses.

- The Company is included in the consolidated federal income tax return with its ultimate parent, F. UnitedHealth Group. The entities included within the consolidated return are included in NAIC Statutory Statement Schedule Y-Information Concerning Activities of Insurer Members Of A Holding Company Group. Federal income taxes are paid to or refunded by UnitedHealth Group pursuant to the terms of a tax-sharing agreement, approved by the Board of Directors, under which taxes approximate the amount that would have been computed on a separate company basis, with the exception of net operating losses and capital losses. For these losses, the Company receives a benefit at the federal rate in the current year for current taxable losses incurred in that year to the extent losses can be utilized in the consolidated federal income tax return of UnitedHealth Group. UnitedHealth Group currently files income tax returns in the U.S. federal jurisdiction, various states, and foreign jurisdictions. The IRS has completed exams on UnitedHealth Group's consolidated income tax returns for fiscal years 2015 and prior. UnitedHealth Group's 2016 tax return is under advance review by the IRS under its Compliance Assurance Program. With the exception of a few states, UnitedHealth Group is no longer subject to income tax examinations prior to 2010 in major state and foreign jurisdictions. The Company does not believe any adjustments that may result from these examinations will be material to the
- G. Tax Contingencies Not applicable.

10. INFORMATION CONCERNING PARENT, SUBSIDIARIES, AND AFFILIATES

A-N. Material Related Party Transactions

Pursuant to the terms of the Agreement, UHS will provide management services to the Company under a fee structure, which is based on a percentage of premium charges representing UHS' expenses for services or use of assets provided to the Company. In addition, UHS provides or arranges for services on behalf of the Company using a pass-through of charges incurred by UHS on a PMPM basis (where the charges incurred by UHS is on a PMPM basis) or using another allocation methodology consistent with the Agreement. These services may include, but are not limited to, integrated personal health management solutions, such as disease management, treatment decision support, and wellness services, including a 24-hour call-in service, access to a network of transplant providers, and discount program services. The amount and types of services provided pursuant to the pass-through provision of the Agreement can change year over year as UHS becomes the contracting entity for services provided to the Company's members. Total administrative services, capitation, and access fees under this arrangement totaled \$357,199,290 and \$323,809,632 in 2016 and 2015, respectively, and are included in total hospital and medical expenses, general administrative expenses, and claims adjustment expenses in the statutory basis statements of operations. Direct expenses not covered under the Agreement, such as broker commissions, Department exam fees, ACA assessments, and premium taxes, are paid by UHS on behalf of the Company. UHS is reimbursed by the Company for these direct expenses.

The Company also directly contracts with related parties to provide services to its members. The Company expensed as hospital and medical expenses, general administrative expenses, and claims adjustment expenses \$26,532,288 and \$38,692,926 in capitation fees paid to related parties during 2016 and 2015, respectively. LifePrint Health, Inc. provides services to health care delivery systems. United Behavioral Health provides mental health and substances abuse services. Dental Benefit Providers, Inc. provides dental care assistances. Sprectra, Inc. provides administrative services related to vision benefit management and claims processing. OptumHealth Care Solutions, Inc. provides chiropractic, physical therapy and complex medical conditions services. The capitation expenses, administrative services, and access fees paid to related parties that are included as hospital and medical expenses, general administrative expenses, and claims adjustment expenses in the statutory basis statements of operations for the years ended December 31, 2016 and 2015, are shown below:

	2016	2015
Lifeprint Health	\$ 16,245,631	\$ 28,718,550
United Behavioral Health	8,020,201	7,920,936
Dental Benefit Providers, Inc.	1,170,515	1,127,726
Spectera, Inc.	984,420	925,714
OptumHealth Care Solutions, Inc.	111,521	-
Total	\$ 26,532,288	\$ 38,692,926

Management believes that its transactions with affiliates are fair and reasonable; however, operations of the Company may not be indicative of those that would have occurred if it had operated as an independent company.

The Company contracts with OptumRx to provide administrative services related to pharmacy management and pharmacy claims processing for its enrollees. Fees related to these agreements, which are calculated on a per- claim basis, of \$27,913,793 and \$25,756,265 in 2016 and 2015, respectively, are included in general administrative expenses and claims adjustment expenses in the statutory basis statements of operations.

The Company contracts with OptumRx to provide personal health products showing the healthcare products and benefit credits needed to redeem the respective products. OptumRx will mail the appropriate personal health products catalogues to the Company's members and manage the personal health products credit balance. OptumRx also distributes personal health products to individual members based upon the terms of the agreement. Fees related to these agreements in 2016 and 2015, which are calculated on a PMPM or per-claim basis of \$4,999,449 and \$2,976,077 respectively, are included in hospital and medical expenses in the statutory basis statements of operations.

The Company has an agreement with OptumInsight, Inc., an affiliate of the Company, for claim analytics, recovery of medical expense overpayments, retroactive fraud, waste and abuse, subrogation and premium audit services. All recoveries are returned to the Company by OptumInsight, Inc. on a monthly basis and a capitated service fee is charged to the Company as a PMPM. Service fees of \$11,761,501 and \$124,805 are included in hospital and medical expenses, claims adjustment expenses, and general administrative expenses in the statutory basis statements of operations for the years ended December 31, 2016 and 2015, respectively.

The Company has premium payments that are received and claim payments that are processed by an affiliated UnitedHealth Group entity. Both premiums and claims applicable to the Company are settled at regular intervals throughout the month via the intercompany settlement process and any amounts outstanding are reflected in receivables from parent, subsidiaries, and affiliates or amounts due to parent, net subsidiaries, and affiliates in the statutory basis statements of admitted assets, liabilities, and capital and surplus.

Effective February 1, 2016, the Company has entered into a facility participation agreement for home infusion therapy services with an affiliated entity, AlexaCare Intermediate Holding, LLC. This agreement has been approved by the Department.

Effective May 1, 2016, the Company has entered into an ancillary provider participation agreement for home urgent care services with an affiliated entity, MedExpress Urgent Care of Boynton Beach, LLC and DWIC of Tampa Bay, Inc. This agreement has been approved by the Department.

Effective September 1, 2015, the Company entered into a reinsurance agreement with an affiliated entity, Unimerica to cede 100% of obligations relating to human organ and bone marrow transplants and related services, infertility treatments and services, mental health and substance abuse treatments and services and chiropractic, physical and occupational therapy treatments and services for musculoskeletal conditions. The agreement has been approved by the Department. Reinsurance premiums, which are calculated on a PMPM rate of earned Medicare and Medicaid member premiums, of \$395,400 and \$47,433 as of December 31, 2016 and 2015, respectively were netted against net premium income in the statutory basis statement of operations. Reinsurance recoveries of \$599,723 and \$0 as of December 31, 2016 and 2015, respectively are included in net reinsurance recoveries in the statutory basis statement of operations. Reinsurance contracts do not relieve the Company from its obligations to policyholders. Failure of reinsurers to honor their obligations could result in losses to the Company.

The Company holds a \$100,000,000 subordinated revolving credit agreement with UnitedHealth Group at an interest rate of London InterBank Offered Rate both plus a margin of 0.50%. This credit agreement is subordinate to the extent it does not conflict with any credit facility held by either party. The credit agreement is for a one-year term and automatically renews annually, unless terminated by either party. The agreement was renewed effective January 1, 2013. No amounts were outstanding under the line of credit as of December 31, 2016 and 2015.

At December 31, 2016 and 2015, the Company reported \$45,775,911 and \$200,065,334, respectively, as amounts due to parent, subsidiaries, and affiliates, net which are included in the statutory basis statements of admitted assets, liabilities, and capital and surplus. These balances are generally settled within 90 days from the incurred date. Any balances due to the Company that are not settled within 90 days are considered nonadmitted assets.

The Company has entered into a Tax Sharing Agreement with UnitedHealth Group (see Note 9).

The Company paid dividends of \$150,000,000 and \$65,000,000 in 2016 and 2015, respectively, to its parent (see Note 13).

The Company does not have any amount deducted from the value of an upstream intermediate entity or ultimate parent owned, either directly or indirectly, via a downstream subsidiary, controlled, or affiliated entity.

The Company does not have any investments in a subsidiary, controlled, or affiliated entity that exceeds 10% of admitted assets.

The Company does not have any investments in impaired subsidiaries, controlled, or affiliated entities.

The Company does not have any investments in foreign insurance subsidiaries.

The Company does not hold any investments in a downstream noninsurance holding company.

The Company does not have any investments in non-insurance subsidiaries, controlled, or affiliated entities.

The Company does not have any investments in insurance subsidiaries, controlled, or affiliated

The Company has not extended any guarantees or undertakings for the benefit of an affiliate or related party.

11. **DEBT**

A–B. The Company had no outstanding debt with third-parties or outstanding Federal Home Loan Bank agreements during 2016 and 2015.

12. RETIREMENT PLANS, DEFERRED COMPENSATION, POSTEMPLOYMENT BENEFITS AND COMPENSATED ABSENCES, AND OTHER POSTRETIREMENT BENEFIT PLANS

A–I. The Company has no defined benefit plans, defined contribution plans, multiemployer plans, consolidated/holding company plans, postemployment benefits, or compensated absences plans and is not impacted by the Medicare Modernization Act on postretirement benefits, since all personnel are employees of UHS, which provides services to the Company under the terms of the Agreement (see Note 10).

13. CAPITAL AND SURPLUS, SHAREHOLDERS' DIVIDEND RESTRICTIONS, AND QUASI-REORGANIZATIONS

- (1–2) The Company has 200,000 shares authorized and 100,000 shares issued and outstanding of \$20 par value common stock. The Company has no preferred stock outstanding. All issued and outstanding shares of common stock are held by the Company's parent, XLHealth.
- (3) Payment of dividends may be restricted by the Department, which generally requires that dividends be paid out of accumulated surplus.
- (4) The Company paid ordinary cash dividends to XLHealth of \$75,000,000, \$75,000,000, \$30,000,000 and \$35,000,000 on December 14, 2016, September 26, 2016, December 17, 2015 and June 15, 2015 respectively, which were approved by the Department and recorded as a reduction to unassigned surplus in the statutory basis statements of admitted assets, liabilities, and capital and surplus.
- (5) The amount of ordinary dividends that may be paid out during any given period is subject to certain restrictions as specified by state statute.
- (6) There are no restrictions placed on the Company's unassigned surplus.
- (7) The Company is not a mutual reciprocal or a similarly organized entity and does not have advances to surplus not repaid.
- (8) The Company does not hold any stock, including stock of affiliated companies for special purposes, such as conversion of preferred stock, employee stock options, or stock purchase warrants.
- (9) As discussed in Note 1, in 2016 no amount is required to be apportioned out of unassigned surplus for the Section 9010 ACA subsequent fee year assessment. For the year ended December 31, 2015, the amount of the estimated Section 9010 ACA subsequent fee year assessment apportioned out of unassigned surplus was \$59,091,827.
- (10) The portion of unassigned surplus, excluding the apportionment of estimated Section 9010 ACA subsequent fee year assessment, net income, and dividends, represented (or reduced) by each item below is as follows:

	2016	2015	Change
Prior year correction of an error	\$ 21,995,512	\$ -	\$ 21,995,512
Net deferred income taxes	\$ 20,769,491	\$ 17,014,964	\$ 3,754,527
Nonadmitted assets	 (55,290,383)	 (46,027,899)	 (9,262,484)
Total	\$ (12,525,380)	\$ (29,012,935)	\$ 16,487,555

(11–13) The Company does not have any outstanding surplus notes and has never been a party to a quasi-reorganization.

14. LIABILITIES, CONTINGENCIES AND ASSESSMENTS

A. Contingent Commitments

The Company has no contingent commitments.

B. Assessments

The Company is not aware of any guarantee fund assessments or premium tax offsets, potential or accrued, that could have a material financial effect ib tge operations of the entity.

C. Gain Contingencies

The Company is not aware of any gain contingencies that should be disclosed in the statutory basis financial statements.

- D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits Not applicable.
- E. Joint and Several Liabilities Not applicable.

F. All Other Contingencies

The Company's business is regulated at the federal, state, and local levels. The laws and rules governing the Company's business and interpretations of those laws and rules are subject to frequent change. Broad latitude is given to the agencies administering those regulations. Further, the Company must obtain and maintain regulatory approvals to market and sell many of its products.

The ACA and the related federal and state regulations will continue to impact how the Company does business and could restrict revenue and enrollment growth in certain products and market segments, restrict premium growth rates for certain products and market segments, increase the Company's medical and administrative costs, expose the Company to an increased risk of liability (including increasing the Company's liability in federal and state courts for coverage determinations and contract interpretation), or put the Company at risk for loss of business. In addition, the Company's statutory basis results of operations, financial condition, and cash flows could be materially adversely affected by such changes. The ACA may create new or expand existing opportunities for business growth, but due to its complexity, the long term impact of the ACA remains difficult to predict and is not yet fully known.

The Company has been, or is currently involved, in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments and other governmental authorities. Certain of the Company's businesses have been reviewed or are currently under review, for reasons including compliance with coding and other requirements under the Medicare risk-adjustment model.

In February 2017, the United States Department of Justice decided to pursue, in part, a *qui tam* lawsuit that previously had been under seal challenging compliance with coding and other requirements under the Medicare risk-adjustment model (the Poehling matter). The Department of Justice and the *qui tam* plaintiff may file amended complaints in the coming months. The Company cannot reasonably estimate the range of loss, if any, that may result from the Poehling matter.

Risk Adjustment Data Validation ("RADV") Audit — CMS adjusts capitation payments to Medicare Advantage plans and Medicare Part D plans according to the predicted health status of each beneficiary as supported by data from health care providers. The Company collects claim and encounter data from providers who the Company generally relies on to appropriately code their claim submissions and document their medical records. CMS then determines the risk score and payment amount for each enrolled member based on the health care data submitted and member demographic information.

CMS and the Office of Inspector General for Health and Human Services periodically perform RADV audits of selected Medicare health plans to validate the coding practices and supporting documentation maintained by health care providers. Such audits have in the past resulted in, and in the future could result in, retrospective adjustments to payments made to the Company, fines, corrective action plans or other adverse action by CMS.

In February 2012, CMS announced a final RADV and payment adjustment methodology audit. It will conduct the RADV audits beginning with the 2011 payment year. These audits involve a review of medical records maintained by care providers and may result in retrospective adjustments to payments made to health plans. CMS has not communicated how the final payment adjustment under its methodology will be implemented.

In May 2016, CMS informed the Company that it had been selected to participate in a RADV audit covering 2012 dates of service (2013 payment year). The Company cannot reasonably estimate the range of loss, if any, that may result from any material government investigations, audits and reviews in which it is currently involved given the inherent difficulty in predicting regulatory action, fines and penalties, if any, and the various remedies and levels of judicial review available to the Company in the event of an adverse finding.

Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company's businesses, including management and administration of health benefit plans and other services.

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred. Although the outcomes of any such legal actions cannot be predicted, in the opinion of management, the resolution of any currently pending or threatened actions will not have a material adverse effect on the statutory basis statements of admitted assets, liabilities, and capital and surplus or statutory basis statements of operations of the Company.

The Company routinely evaluates the collectability of all receivable amounts included in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Impairment reserves are established for those amounts where collectability is uncertain. Based on the Company's past experience, exposure related to uncollectible balances and the potential of loss for those balances not currently reserved for is not material to the Company's statutory basis financial condition.

There are no assets that the Company considers to be impaired at December 31, 2016 and 2015, except as disclosed in Note 5 and Note 20.

15. LEASES

A–B. According to the management agreement between the Company and UHS (see Note 10), operating leases for the rental of office facilities and equipment are the responsibility of UHS. Fees associated with the lease agreements are included as a component of the Company's management fee.

16. INFORMATION ABOUT FINANCIAL INSTRUMENTS WITH OFF-BALANCE-SHEET RISK AND FINANCIAL INSTRUMENTS WITH CONCENTRATIONS OF CREDIT RISK

(1–4) The Company does not hold any financial instruments with off-balance-sheet risk or have any concentrations of credit risk.

17. SALE, TRANSFER, AND SERVICING OF FINANCIAL ASSETS AND EXTINGUISHMENTS OF LIABILITIES

A–C. The Company did not participate in any transfer of receivables, financial assets, or wash sales.

18. GAIN OR LOSS TO THE REPORTING ENTITY FROM UNINSURED PLANS AND THE UNINSURED PORTION OF PARTIALLY INSURED PLANS

A–B. The Company has no operations from Administrative Services Only Contracts or Administrative Services Contracts in 2016 and 2015.

C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract

The Medicare Part D program is a partially insured plan. The Company recorded a receivable of \$63,926,966 and \$101,717,299 at December 31, 2016 and 2015, respectively, for cost reimbursements under the Medicare program for the catastrophic reinsurance and low-income member cost-sharing subsidies as described in Note 1, *Amounts Receivable Relating to Uninsured Plans* and *Liability for Amounts Held Under Uninsured Plans*. The Company also recorded a receivable of \$9,101,107 and \$4,747,084 and also a payable of \$4,657,092 and \$148,080 at December 31, 2016 and 2015, respectively, for the Medicare Part D CGDP as described in Note 1, *Amounts Receivable Relating to Uninsured Plans* and *Liability for Amounts Held Under Uninsured Plans*.

19. DIRECT PREMIUM WRITTEN/PRODUCED BY MANAGING GENERAL AGENTS/THIRD-PARTY ADMINISTRATORS

The Company did not have any direct premiums written or produced by managing general agents or third-party administrators in 2016 and 2015.

20. FAIR VALUE MEASUREMENT

The NAIC SAP defines fair value, establishes a framework for measuring fair value, and outlines the disclosure requirements related to fair value measurements. The fair value hierarchy is as follows:

Level 1—Quoted (unadjusted) prices for identical assets in active markets.

Level 2—Other observable inputs, either directly or indirectly, including:

- Quoted prices for similar assets in active markets;
- Quoted prices for identical or similar assets in nonactive markets (few transactions, limited information, noncurrent prices, high variability over time, etc.);
- Inputs other than quoted prices that are observable for the asset (interest rates, yield curves, volatilities, default rates, etc.);
- Inputs that are derived principally from or corroborated by other observable market data.

Level 3—Unobservable inputs that cannot be corroborated by observable market data.

The estimated fair values of bonds and short term investments are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service ("pricing service"), which generally uses quoted prices or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, making adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, non-binding broker quotes, benchmark yields, credit spreads, default rates, and prepayment speeds. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to a secondary pricing source, prices reported by its custodian, its investment consultant, and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company's internal price verification procedures and review of fair value methodology documentation provided by independent pricing services have not historically resulted in an adjustment in the prices obtained from the pricing service.

In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest-level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

A. Fair Value

b.

(1) Fair Value Measurements at Reporting Date

The Company does not have financial assets measured and reported at fair value at December 31, 2016. The following table presents information about the Company's financial assets that are measured and reported at fair value at December 31, 2015 in the statutory basis statements of admitted assets, liabilities, and capital and surplus according to the valuation techniques the Company used to determine their fair values:

Description for Each	December 31, 2015					
Class of Asset or Liability	(Level 1)	(Level 2)	(Level 3)	Total		
Assets at fair value:						
Perpetual preferred stock:						
Industrial and misc	\$ -	\$ -	\$ -	\$ -		
Parent, subsidiaries, and affiliates		-		-		
Total perpetual preferred stocks				<u> </u>		
Bonds:						
U.S. governments	-	-	-	-		
Industrial and misc	-	1,150,500	-	1,150,500		
Hybrid securities	-	-	-	-		
Parent, subsidiaries, and affiliates		-		-		
Total bonds		1,150,500		1,150,500		
Common stock:						
Industrial and misc	-	-	-	-		
Parent, subsidiaries, and affiliates						
Total common stock						
Derivative assets:						
Interest rate contracts	-	-	-	-		
Foreign exchange contracts	-	-	-	-		
Credit contracts	-	-	-	-		
Commodity futures contracts	-	-	-	-		
Commodity forward contracts						
Total derivatives	-	-	-	-		
Additional write-ins	-	-	-	-		
Additional write-ins	-	-	-	-		
Separate account assets						
Total assets at fair value	<u>\$ -</u>	\$ 1,150,500	<u>\$ -</u>	\$ 1,150,500		
. Liabilities at fair value:						
Derivative liabilities	\$ -	\$ -	\$ -	\$ -		
Additional write-ins	-	-	-	-		
Additional write-ins				-		
Total liabilities at fair value	<u>\$ -</u>	<u>\$</u> -	\$ -	<u>\$ - </u>		

There were no transfers between Levels 1 and 2 during the years ended December 31, 2016 and 2015.

- (2) The Company does not have any financial assets with a fair value hierarchy of Level 3 that were measured and reported at fair value.
- (3) Transfers between fair value hierarchy levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs. There were no transfers between Levels 1, 2 or 3 of any financial assets or liabilities during the years ended December 31, 2016 or 2015.

- Investments Fair values of debt securities are based on quoted market prices, where available. The Company obtains one price for each security primarily from a pricing service, which generally uses quoted prices or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, and, if necessary, makes adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment speeds and non-binding broker quotes. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to prices reported by a secondary pricing source, such as its custodian, its investment consultant and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company's internal price verification procedures and reviews of fair value methodology documentation provided by independent pricing services have not historically resulted in adjustment in the prices obtained from the pricing service.
- (5) The Company has no derivative assets and liabilities to disclose.
- B. Fair Value Combination Not applicable.

C. Aggregate Fair Value Hierarchy

The aggregate fair value by hierarchy of all financial instruments as of December 31, 2016 and 2015 is presented in the table below:

			2016			
Types of Financial Investment	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Not Practicable (Carrying Value)
U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities Money-market funds	\$ 52,477,133 59,503,971 95,988,121 127,696,837 15,365,292	\$ 54,446,628 60,147,620 96,891,099 127,868,529 15,365,292	\$ 36,307,752 - - - - - 15,365,292	\$ 16,169,381 59,503,971 95,988,121 127,696,837	\$ - - -	\$ - - -
Total bonds and short-term investments	\$ 351,031,354	\$ 354,719,168	\$ 51,673,044 2015	\$ 299,358,310	<u> </u>	<u>\$ -</u>
Types of Financial Investment	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Not Practicable (Carrying Value)
U.S. government and agency securities State and agency municipal securities City and county municipal securities Corporate debt securities Money-market funds	\$ 99,081,505 90,845,841 133,352,487 163,505,434 5,839,795	\$ 99,137,016 89,884,650 131,647,766 165,078,953 5,839,795	\$ 49,977,229 - - - - 5,839,795	\$ 49,104,276 90,845,841 133,352,487 163,505,434	\$ - - - - -	\$ - - - - -
Total bonds and short-term investments	\$ 492,625,062	\$ 491,588,180	\$ 55,817,024	\$ 436,808,038	<u>\$ -</u>	\$ -

Included as Level 1 in U.S. government and agency securities in the fair value hierarchy tables above are U.S. Treasury securities of \$36,307,752 and \$49,977,229 as of December 31, 2016 and December 31, 2015, respectively.

There are no commercial paper investments included in corporate debt securities in the fair value hierarchy tables above as of December 31, 2016 and 2015.

D. Not Practicable to Estimate Fair Value — Not applicable.

21. OTHER ITEMS

The Company is committed to maintaining adequate operating cash and required capital and surplus levels to fund the run-out of operations. In addition, the Company is part of a holding company system, which the parent is committed to and has the financial resources for this Company to meet all of its financial obligations. In the event of an immediate and material cash demand, a surplus infusion would be executed to address cash requirements. There are no restrictions, which would preclude this from happening in a timely manner.

- **A.** The Company did not encounter any unusual or infrequent items for the years ended December 31, 2016 and 2015.
- B. The Company has no troubled debt restructurings as of December 31, 2016 and 2015.

- **C.** The Company does not have any amounts not recorded in the statutory basis financial statements that represent segregated funds held for others. The Company also does not have any exposures related to forward commitments that are not derivative instruments.
- **D.** The Company has not received any business interruption insurance recoveries during 2016 and 2015.
- **E.** The Company has no transferable or non-transferable state tax credits.

F. Sub-Prime Mortgage-Related Risk Exposure

- (1) The investment policy for the Company limits investments in loan-backed securities, which includes sub-prime issuers. Further, the policy limits investments in private-issuer mortgage securities to 10% of the portfolio, which also includes sub-prime issuers. The exposure to unrealized losses on sub-prime issuers is due to changes in market prices. There are no realized losses due to not receiving anticipated cash flows. The investments covered are NAIC rating of 1 or 2.
- (2) The Company has no direct exposure through investments in sub-prime mortgage loans.
- (3) The Company has no direct exposure through other investments.
- (4) The Company has no underwriting exposure to sub-prime mortgage risk through mortgage
- **G.** The Company does not have any retained asset accounts for beneficiaries.
- **H.** As of December 31, 2016, the Company is not aware of any possible proceeds of insurance-linked securities.

22. EVENTS SUBSEQUENT

Subsequent events have been evaluated through February 27, 2017, which is the date these statutory basis financial statements were available for issuance.

<u>TYPE I — Recognized Subsequent Events</u>

There are no events subsequent to December 31, 2016, that require recognition and disclosure.

TYPE II — Non-Recognized Subsequent Events

The Company is subject to the annual fee under Section 9010 of the ACA. The fee is allocated to individual health insurers based on the ratio of the amount of the entity's net premiums written during the preceding calendar year to the amount of the health insurance for any U.S. health risk that is written during the preceding calendar year. A health insurance entity's portion of the annual fee becomes payable once the entity provides health insurance for any U.S. health risk for each calendar year beginning on or after January 1, of the year the fee is due. Pursuant to the 2017 HIF moratorium (see Note 1), no HIF will be payable in 2017 and therefore there will be no amounts apportioned out of unassigned funds in 2016 representing an estimate of the 2017 HIF.

The table below presents information regarding the annual fee under Section 9010 of the ACA as of December 31, 2016 and 2015:

	Current Year	Prior Year
A. Did the reporting entity write accident and health insurance premium that is subject to Section 9010 of the Federal Affordable Care Act (YES/NO)?	Yes	-
B. ACA fee assessment payable for the upcoming year	\$ -	\$ 59,091,827
C. ACA fee assessment paid	59,352,568	57,607,559
D. Premium written subject to ACA 9010 assessment	-	3,323,004,592
E. Total Adjusted Capital before surplus adjustment (Five-Year Historical Line 14)	423,064,238	
F. Total Adjusted Capital after surplus adjustment (Five-Year Historical Line 14 minus 22B above)	423,064,238	
G. Authorized Control Level (Five-Year Historical Line 15)	114,581,564	
H. Would reporting the ACA assessment as of December 31, 2016, have triggered an RBC action level (YES/NO)?	No	-

Effective January 1, 2017, the Company novated a CMS contract to affiliate, UnitedHealthcare Insurance Company ("UHIC"). The novation agreement resulted in full control of the contract being transferred to UHIC at \$0 net book value for dates of service on or after January 1, 2017. Approval for this novation was received from CMS, the Department, and Connecticut Insurance Department. The 2016 Medicare revenue subject to the novation represented approximately 67% of total direct premiums written.

There are no other events subsequent to December 31, 2016 that require disclosure.

23. REINSURANCE

The Company does not have any unaffiliated reinsurance agreements in place as of December 31, 2016.

Reinsurance Agreements — In the normal course of business, the Company seeks to reduce potential losses that may arise from catastrophic events that cause unfavorable underwriting results by reinsuring certain levels of such risk with affiliated (see Note 10) and other nonaffiliated reinsurers. The Company remains primarily liable as the direct insurer on all risks reinsured.

A. Ceded Reinsurance Report

Section 1 — General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

Yes () No (X)

(2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor, or any other person not primarily engaged in the insurance business?

Yes () No (X)

Section 2 — Ceded Reinsurance Report — Part A

(1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credit?

Yes () No (X)

(2) Does the reporting entity have any reinsurance agreements in effect that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

Section 3 — Ceded Reinsurance Report — Part B

(1) What is the estimated amount of the aggregate reduction in surplus (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of all reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate.

The Company estimates there should be no aggregate reduction in surplus for termination of all reinsurance agreements as of December 31, 2016.

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?

Yes () No (X)

B. Uncollectible Reinsurance — During 2016 and 2015, there were no uncollectible reinsurance recoverables.

- C. Commutation of Ceded Reinsurance There was no commutation of reinsurance in 2016 or 2015.
- D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation Not applicable.

24. RETROSPECTIVELY RATED CONTRACTS AND CONTRACTS SUBJECT TO REDETERMINATION

- **A**. The Company estimates accrued retrospective premium adjustments for its group health insurance business based on mathematical calculations in accordance with contractual terms.
- **B**. Estimated accrued retrospective premiums due from the Company are recorded in aggregate health policy reserves in the statutory basis statements of admitted assets, liabilities, and capital and surplus and as an adjustment to change in unearned premium reserves and reserve for rate credits in the statutory basis statements of operations.
- C. The Company has Medicare Part D risk-corridor amounts from CMS which are subject to a retrospectively rated feature related to Part D premiums. The Company has estimated accrued retrospective premiums related to certain Part D premiums based on guidelines determined by CMS. The formula is tiered and based on the bid medical loss ratio. The amount of Medicare Part D direct premiums written subject to this retrospectively rated feature was \$200,479,833 and \$229,055,999 representing, 5.5% and 6.9% of total direct premiums written for 2016 and 2015, respectively.

The Company has risk-adjustment amounts from CMS which are subject to a redetermination feature related to Medicare premiums. The Company has estimated premium adjustments for changes to each member's health scores based on guidelines determined by CMS. The total amount of Medicare direct premiums written for which a portion is subject to redetermination features was \$3,681,663,451 and \$3,311,012,114 representing, 100% of total direct premiums written for 2016 and 2015, respectively.

D. The Company does not have comprehensive commercial business subject to specific minimum loss ratio requirements as of December 31, 2016 and 2015. The Company is required to maintain a specific minimum loss ratio on the Medicare line of business. The following table discloses the minimum medical loss ratio rebate liability which is included in aggregate health policy reserves in the statutory basis statements of admitted assets, liabilities, and capital and surplus for the years ended December 31, 2016 and 2015:

	1 Individual	2 3 Small Large Group Group Employer Employer		4 Other Categories with Rebates	5 Total
Prior reporting year					
(1) Medical loss ratio rebates incurred	\$ -	\$ -	\$ -	\$ -	\$ -
(2) Medical loss ratio rebates paid	-	-	-	-	-
(3) Medical loss rebates unpaid	-	-	-	-	-
(4) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	-
(5) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	-
(6) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	-
Current reporting year-to-date					
(7) Medical loss ratio rebates incurred	-	-	-	7,158,971	7,158,971
(8) Medical loss ratio rebates paid	-	-	-	-	-
(9) Medical loss rebates unpaid	-	-	-	7,158,971	7,158,971
(10) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	-
(11) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	-
(12) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	7,158,971

E. Risk-Sharing Provisions of the Affordable Care Act

(1–5) The Company did not write accident and health premiums in 2016 and 2015 subject to the risk-sharing provisions of the ACA.

25. CHANGE IN INCURRED CLAIMS AND CLAIMS ADJUSTMENT EXPENSES

Changes in estimates related to the prior year incurred claims are included in total hospital and medical expenses in the current year in the statutory basis statements of operations. The following tables disclose paid claims, incurred claims, and the balance in the claims unpaid, accrued medical incentive pool and bonus amounts, aggregate health claim reserves, and health care receivables for the years ended December 31, 2016 and 2015:

	Current Year Incurred Claims	Prior Years Incurred Claims	Total
Beginning of year claim reserve Paid claims—net of health care receivable End of year claim reserve	\$ - 2,490,782,238 482,637,929	\$ (336,586,231) 176,791,141 50,595,176	\$ (336,586,231) 2,667,573,379 533,233,105
Incurred claims excluding the change in recoverables as presented below	2,973,420,167	(109,199,914)	2,864,220,253
Beginning of year health care receivable End of year health care receivable		147,499,440 (35,268,301)	147,499,440 (176,981,211)
Total incurred claims	\$ 2,831,707,257	\$ 3,031,225	\$ 2,834,738,482

	2015				
	Current Year Incurred Claims	Prior Years Incurred Claims	Total		
Beginning of year claim reserve Paid claims—net of health care receivable End of year claim reserve	\$ - 2,530,771,188 330,314,735	\$ (198,696,825) 155,403,668 6,271,496	\$ (198,696,825) 2,686,174,856 336,586,231		
Incurred claims excluding the change in health care receivable as presented below	2,861,085,923	(37,021,661)	2,824,064,262		
Beginning of year health care receivable* End of year health care receivable*	(125,742,432)	106,520,418 (21,757,008)	106,520,418 (147,499,440)		
Total incurred claims	\$ 2,735,343,491	\$ 47,741,749	\$ 2,783,085,240		

The liability for claims unpaid, accrued medical incentive pool and bonus amounts, and aggregate health claim reserves, net of health care receivable as of December 31, 2015 was \$189,086,791. As of December 31, 2016, \$176,791,141 has been paid for incurred claims attributable to insured events of prior years. Reserves remaining for prior years, net of health care receivable are now \$15,326,875, as a result of re-estimation of unpaid claims. Therefore, there has been \$3,031,225 unfavorable prior year development since December 31, 2015 to December 31, 2016. The primary drivers consist of unfavorable development of \$29,686,597 in retroactivity for inpatient, outpatient, physician, and pharmacy claims, unfavorable development in provider settlements of \$2,944,965 offset by favorable development as a result of a change in the provision for adverse deviations in experience of \$14,149,565, favorable development in Part D of \$10,118,903, favorable development in risk share of \$4,436,501, favorable development in capitation of \$549,605, and favorable development in Rx Rebates of \$240,859. At December 31, 2015, the Company recorded \$47,741,749 unfavorable prior year development of \$55,784,236 in retroactivity for inpatient, outpatient, physician, and pharmacy claims offset by favorable development as a result of a change in the provision for adverse deviations in experience of \$11,374,499. The unfavorable development in 2015 was materially impacted by a higher than anticipated decline in the amount of actual and estimated retracted claims. Original estimates are increased or decreased, as additional information becomes known regarding individual claims. Included in this development is the impact related to retrospectively rated policies. As a result of the prior year effects, on a regular basis, the Company adjusts revenue and the corresponding liability and/or receivable related to retrospectively rated policies and the impact of the change is included as a component of change in unearned premium reserves and reserve for rate credits in the statutory basis statements of operations.

The Company incurred claims adjustment expenses of \$136,968,400 and \$142,305,460 in 2016 and 2015, respectively. These costs are included in the management service fees paid by the Company to UHS as a part of its management agreement (see Note 10). The following table discloses paid CAE, incurred CAE, and the balance in the unpaid claim adjustment expenses reserve for 2016 and 2015:

	2016	2015
Total claims adjustment expenses	\$ 136,968,400	\$ 142,305,460
Less current year unpaid claims adjustment expenses	(4,781,900)	(3,555,613)
Add prior year unpaid claims adjustment expenses	3,555,613	1,900,801
Total claims adjustment expenses paid	\$ 135,742,113	\$ 140,650,648

26. INTERCOMPANY POOLING ARRANGEMENTS

A-G. The Company did not have any intercompany pooling arrangements in 2016 or 2015.

27. STRUCTURED SETTLEMENTS

A-B. The Company did not have structured settlements in 2016 or 2015.

28. HEALTH CARE AND OTHER AMOUNTS RECEIVABLE

A. Pharmacy rebates receivable are recorded when reasonably estimated or billed by the affiliated pharmaceutical benefit manager in accordance with pharmaceutical rebate contract provisions. Information used to support rebates billed to the manufacturer is based on utilization information gathered by the pharmaceutical benefit manager and adjusted for significant changes in pharmaceutical contract provisions.

The Company evaluates admissibility of all pharmacy rebates receivable based on the administration of each underlying pharmaceutical benefit management agreement. The Company has nonadmitted and excluded all pharmacy rebates receivable that do not meet the admissibility criteria of SSAP No. 84, *Certain Health Care Receivables and Receivables under Government Insured Plans* ("SSAP No. 84") from the statutory basis statements of admitted assets, liabilities, and capital and surplus.

For each pharmaceutical management agreement for which a portion of the total pharmacy rebates receivable can be admitted based on the admissibility criteria of SSAP No. 84, the pharmacy rebate transaction history is summarized as follows:

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received within 90 Days of Billing	Actual Rebates Received within 91 to 180 Days of Billing	Actual Rebates Received More than 180 Days after Billing
12/31/2016	\$ 85,425,366	\$ -	\$ -	\$ -	\$ -
9/30/2016	87,401,055	86,595,869	49,940,002	-	-
6/30/2016	84,897,767	83,968,224	69,615,561	11,355,405	-
3/31/2016	78,345,541	77,425,121	64,649,709	10,969,078	1,119,371
12/31/2015	77,226,595	77,989,147	68,395,605	8,783,513	121,526
9/30/2015	74,001,419	74,474,159	63,434,826	4,907,814	6,047,120
6/30/2015	69,160,137	69,745,299	57,567,454	9,460,250	2,480,054
3/31/2015	62,165,498	61,772,300	45,088,727	13,512,737	3,360,293
12/31/2014 9/30/2014 6/30/2014 3/31/2014	51,958,525 47,027,114 42,030,825 38,189,497	52,443,945 46,756,025 41,907,233 37,988,701	43,156,510 37,927,735 33,866,735 30,964,830	7,712,193 7,430,333 6,466,567 6,133,201	1,254,646 1,458,895 1,559,123 739,942

Of the amount reported as health care receivables, \$120,343,602 and \$103,719,598 relates to pharmacy rebates receivable as of December 31, 2016 and 2015, respectively. This increase is primarily due to increased membership along with the change in generic/name brand mix.

B. The Company does not have any risk-sharing receivables.

29. PARTICIPATING POLICIES

The Company did not have any participating contracts in 2016 or 2015.

30. PREMIUM DEFICIENCY RESERVES

The Company has not recorded any premium deficiency reserves as of December 31, 2016 or 2015. The analysis of premium deficiency reserves was completed as of December 31, 2016 and 2015. The Company did consider anticipated investment income when calculating the premium deficiency reserves.

The following table summarizes the Company's premium deficiency reserves as of December 31, 2016 and 2015:

		2016
Liability carried for premium deficiency reserves	\$	-
2. Date of the most recent evaluation of this liability	12	/31/2016
3. Was anticipated investment income utilized in this calculation?	Yes 🗀	X No
		2015
Liability carried for premium deficiency reserves	\$	-
2. Date of the most recent evaluation of this liability	12	/31/2015
3. Was anticipated investment income utilized in this calculation?	Yes 🗀	X No

31. ANTICIPATED SALVAGE AND SUBROGATION

Due to the type of business being written, the Company has no salvage. As of December 31, 2016 and 2015, the Company had no specific accruals established for outstanding subrogation, as it is considered a component of the actuarial calculations used to develop the estimates of claims unpaid and aggregate health claim reserves.

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System conis an insurer?			Yes [X] No []
	If yes, complete Schedule Y, Parts 1, 1A and 2				
1.2	If yes, did the reporting entity register and file with its domiciliary State Insurance such regulatory official of the state of domicile of the principal insurer in the Hoproviding disclosure substantially similar to the standards adopted by the Natic its Model Insurance Holding Company System Regulatory Act and model regulatory to standards and disclosure requirements substantially similar to those	Iding Company System, a registration statement nal Association of Insurance Commissioners (NAIC) in lations pertaining thereto, or is the reporting entity	Yes ['	X] No [] N/A []
1.3	State Regulating?			Arkan	sas
2.1	Has any change been made during the year of this statement in the charter, by- reporting entity?			Yes [] No [X]
2.2	If yes, date of change:				
3.1	State as of what date the latest financial examination of the reporting entity was	made or is being made.		12/31/	2013
3.2	State the as of date that the latest financial examination report became available entity. This date should be the date of the examined balance sheet and not the			12/31/	2013
3.3	State as of what date the latest financial examination report became available to domicile or the reporting entity. This is the release date or completion date of the examination (balance sheet date).	ne examination report and not the date of the		06/22/	2015
3.4	By what department or departments? Arkansas Department of Insurance				
3.5	Have all financial statement adjustments within the latest financial examination statement filed with Departments?	report been accounted for in a subsequent financial	Yes [] No [] N/A [X]
3.6	Have all of the recommendations within the latest financial examination report by	een complied with?	Yes [] No [] N/A [X]
4.1		he reporting entity), receive credit or commissions for or neasured on direct premiums) of: business?			
4.2	4.12 renewals? During the period covered by this statement, did any sales/service organization receive credit or commissions for or control a substantial part (more than 20 per premiums) of:			Yes [] No [X]
		business?] No [X]] No [X]
5.1	Has the reporting entity been a party to a merger or consolidation during the per			•	
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of domic ceased to exist as a result of the merger or consolidation.	ile (use two letter state abbreviation) for any entity that h	as		
	1 Name of Entity	2 3 NAIC Company Code State of Domicile			
6.1	Has the reporting entity had any Certificates of Authority, licenses or registration revoked by any governmental entity during the reporting period?			Yes [] No [X]
6.2	If yes, give full information:				
7.1	Does any foreign (non-United States) person or entity directly or indirectly control	ol 10% or more of the reporting entity?		Yes [] No [X]
7.2	If yes, 7.21 State the percentage of foreign control;			(0.0 %
	7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the entity is attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporati		_		·
	1 Nationality	2 Type of Entity			
			l l		

8.1 8.2	2 If response to 8.1 is yes, please identify the name of the bank holding company.					Yes [] N	o [X]
8.3 8.4	Is the company affiliated with one or more banks, thrifts or set if response to 8.3 is yes, please provide below the names and regulatory services agency [i.e. the Federal Reserve Board (Insurance Corporation (FDIC) and the Securities Exchange	curities firms?d location (city and state of the main office) of any affil FRB), the Office of the Comptroller of the Currency (liates regulated	d by a fed	deral	Yes [X	[] N	o []
	1	2	3	4	5	6	7	
	Affiliate Name	Location (City, State)	FRB	OCC	FDIC	SEC	_	
	Optum Bank, Inc.	Sait Lake City, UI	NO	NO	YES	NO		
9.	What is the name and address of the independent certified pu	ublic accountant or accounting firm retained to conduc	ct the annual a	udit?			_	
	Baker Tilly Virchow Krause LLP, Minneapolis, MN 55402							
10.1	Has the insurer been granted any exemptions to the prohibite requirements as allowed in Section 7H of the Annual Financ law or regulation?	ial Reporting Model Regulation (Model Audit Rule), o	r substantially	similar st	ate	Yes [] N	o [X]
10.2						_		
	Has the insurer been granted any exemptions related to the or allowed for in Section 18A of the Model Regulation, or subst If the response to 10.3 is yes, provide information related to the	antially similar state law or regulation?	Model Regulat	ion as		Yes [] N	o [X]
		·						
10.5 10.6	Has the reporting entity established an Audit Committee in co If the response to 10.5 is no or n/a, please explain] No []	N/A []
11.	What is the name, address and affiliation (officer/employee of firm) of the individual providing the statement of actuarial op Mary J. Murley, Chief Actuary of UnitedHealthcare Medicare a Company is an affiliate, 9800 Health Care Lane, Minnetonka	the reporting entity or actuary/consultant associated inion/certification? and Retirement of which Care Improvement Plus Sou	with an actuar th Central Insu	ial consu	Iting			
12.1	Does the reporting entity own any securities of a real estate h	olding company or otherwise hold real estate indirectl	y?			Yes [] N	o [X]
	12.11 Name of real estate holding company							
		per of parcels involved						
12.2	12.13 Total If, yes provide explanation:	book/adjusted carrying value				\$		0
13. 13.1	FOR UNITED STATES BRANCHES OF ALIEN REPORTING What changes have been made during the year in the United	States manager or the United States trustees of the						
13.2	Does this statement contain all business transacted for the re					Yes [] N	0 [] 0
13.3	Have there been any changes made to any of the trust indent	ures during the year?				Yes [
13.4]	N/A []
14.1						Yes [X	[] N	0[]
	(b) Full, fair, accurate, timely and understandable disclosure in (c) Compliance with applicable governmental laws, rules and		ting entity;					
	(d) The prompt internal reporting of violations to an appropriat	te person or persons identified in the code; and						
14 11	(e) Accountability for adherence to the code. If the response to 14.1 is No, please explain:							
7.11	ii the response to 14.1 is No, please explain.							
	Has the code of ethics for senior managers been amended? .					Yes [] N	o [X]
14.21	If the response to 14.2 is yes, provide information related to a	• ,						
14.3	Have any provisions of the code of ethics been waived for any	y of the specified officers?				Yes [] N	o [X]
	If the response to 14.3 is yes, provide the nature of any waive	•						

15.1	5.1 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List?					Yes [1 No [Y 1
15.2	If the response to 15.1 is	s yes, indicate the American Bankers Association (redit and describe the circumstances in which the L	ABA) Routing Number	and the name of the issuing or confirm	ning	ies į] NO [v 1
	1 American Bankers	2		3		4	ļ	
	Association (ABA) Routing Number	Issuing or Confirming Bank Name		That Can Trigger the Letter of Credit		Amo		
							<u></u>	
16.		of all investments of the reporting entity passed upon		of directors or a subordinate committee		V . F . V	. N. F	1
17.	Does the reporting entity	y keep a complete permanent record of the procee	dings of its board of dire	ectors and all subordinate committees	3	Yes [X Yes [X		
18.	Has the reporting entity	an established procedure for disclosure to its boards, directors, trustees or responsible employees that	d of directors or trustee	s of any material interest or affiliation	on the	Yes [X		-
			NANCIAL					
19.	Has this statement beer Accounting Principles)	n prepared using a basis of accounting other than S ?	Statutory Accounting Pr	inciples (e.g., Generally Accepted		Yes [] No [Х]
20.1	Total amount loaned du	ring the year (inclusive of Separate Accounts, exclu	usive of policy loans):	20.11 To directors or other officers		\$		0
				20.12 To stockholders not officers		\$		0
				20.13 Trustees, supreme or grand (Fraternal Only)		\$		0
20.2		utstanding at the end of year (inclusive of Separate	Accounts, exclusive of	f				
	policy loans):			20.21 To directors or other officers 20.22 To stockholders not officers		.\$ Ф		٥
				20 23 Trustage curreme or grand				
				(Fraternal Only)		\$		0
21.1	Were any assets reporte	ed in this statement subject to a contractual obligat	ion to transfer to anothe	er party without the liability for such		l acV	1 No [V 1
21 2		ed in the statement?thereof at December 31 of the current year:		21.21 Rented from others		162 [C] INO [۷]
	ii yoo, otato tilo allioalit	and our at Booth Bor o'r o'r the dan one year.		21.22 Borrowed from others				
				21.23 Leased from others				
				21.24 Other		\$		0
22.1	Does this statement including a	lude payments for assessments as described in the ssessments?	Annual Statement Ins	tructions other than guaranty fund or				
22.2	If answer is yes:	330331101101		2.21 Amount paid as losses or risk adj				
			22	2.22 Amount paid as expenses		\$	59,35	52,568
			22	2.23 Other amounts paid		\$		0
		y report any amounts due from parent, subsidiaries						
23.2	If yes, indicate any amo	unts receivable from parent included in the Page 2	amount:			\$		0
		INV	ESTMENT					
24.01		nds and other securities owned December 31 of cu of the reporting entity on said date? (other than sec				Yes [X] No []
24.02	, 0	lete information relating thereto						
24.03	whether collateral is ca	grams, provide a description of the program includi arried on or off-balance sheet. (an alternative is to r	eference Note 17 where	e this information is also provided)				
24.04		ccurity lending program meet the requirements for a			Yes [] No [] N/A	[X]
24.05	If answer to 24.04 is yes	s, report amount of collateral for conforming program	ns			\$		0
24.06	If answer to 24.04 is no,	report amount of collateral for other programs				\$		0
24.07		nding program require 102% (domestic securities) a			Yes [] No [] N/A	[X]
24.08	Does the reporting entity	y non-admit when the collateral received from the c	ounterparty falls below	100%?	Yes [] No [] N/A	[X]
24.09	Does the reporting entity	y or the reporting entity 's securities lending agent ι	utilize the Master Secur	rities lending Agreement (MSLA) to	Vac I	1 No [1 NI/A	[V]

24.10	For the reporting entity's security lending progra	am state the amount of t	the following as Decen	nber 31 of the curren	t year:		
	24.101 Total fair value of reinv	ested collateral assets re	eported on Schedule I	DL, Parts 1 and 2		\$	
	24.102 Total book adjusted/carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2						
	24.103 Total payable for secur	ities lending reported on	the liability page			\$	
25.1	Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity, or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 24.03).					Yes [X] No []	
25.2	If yes, state the amount thereof at December 3	1 of the current year:	25 21 S	uhiect to renurchase	agreements	\$	
20.2	in yee, state the amount thereof at Beschiber o	Tortho current your.			urchase agreements		
					chase agreements		
					ar repurchase agreements		
			25.25 P	laced under option a	greements	\$	
			25.26 Le	etter stock or securiti	es restricted as to sale -	•	
			25.27.51	excluding FHLB Cap	ital Stock	\$	
			25.27 FI 25.28 ∩	n denocit with ctates		⊅	
			25.20 O	n deposit with other	regulatory bodies	\$	
			25.30 P	ledged as collateral -	excluding collateral pledged	to	
			ä	an FHLB		\$	
			25.31 P	ledged as collateral t	o FHLB - including assets ements	•	
			25.32 ∩	backing funding agre	ements	\$	
			25.52 0	u ici		Ф	
25.3	For category (25.26) provide the following:						
	1			2		3	
	Nature of Restriction			Description		Amount	
26.1 26.2	Does the reporting entity have any hedging translation of the last section of the last						
	If no, attach a description with this statement.						
27.1	Were any preferred stocks or bonds owned as issuer, convertible into equity?	of December 31 of the c	current year mandatori	ly convertible into eq	uity, or, at the option of the	Yes [] No [X]	
27.2	If yes, state the amount thereof at December 3	1 of the current year				\$	
28.	Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III - General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping Agreements of the NAIC Financial Condition Examiners Handbook?						
28.01	For agreements that comply with the requirement	ents of the NAIC Financia	al Condition Examiner	s Handbook, comple	te the following:		
	1 Name of Custodian(s)			2 Custodian's	Address		
	Northern Trust	50 S. LaSa	alle, Chicago, IL 606		Audiess		
	Bank of New York Mellon		-		New York NY 10286		
28.02	For all agreements that do not comply with the and a complete explanation:	requirements of the NAI	C Financial Condition	Examiners Handboo	k, provide the name, location	n	
	1 Name(s)		2 Location(s)		3 Complete Explana	tion(s)	
	Trainio(0)						
28.03 28.04	Have there been any changes, including name If yes, give full and complete information relatin		an(s) identified in 28.0				
	1	2		3	4		
	Old Custodian	New Cus	stodian	Date of Change	Reaso	on	

		s on behalf of the reporting entity. For as s to the investment accounts"; "handle			nally by emplo	yees of the	reporting entity, not	e as			
		1		2							
		lame of Firm or Individual		Affiliation U							
	Internally Managed			I							
	28.0597 For those firms/ind designated with a "	ividuals listed in the table for Question 2 U") manage more than 10% of the report Is unaffiliated with the reporting entity (i.e. management aggregate to more than 50	28.05, do any rting entity's e. designated	r firms/individual: assets?	ed in the table	for Questic	on 28.05, does the			No [No [
28.06	For those firms or individual the table below.	s listed in the table for 28.05 with an affi	iliation code	of "A" (affiliated)	or "U" (unaffi	liated), prov	ride the information	or			
	1	2		3			4		Τ	5	
										estmei ageme	
	Central Registration Depository Number	Name of Firm or Individua		Legal Entity Ide	entifier (LEI)		Registered With		(IM	reeme IA) File	d
	107738	Goldman Sachs		CF5M58QA35CFPUX					NO		
29.1 29.2	Does the reporting entity ha Exchange Commission (SI If yes, complete the followin	ve any diversified mutual funds reported EC) in the Investment Company Act of 1 g schedule:	d in Schedule 1940 [Section	D, Part 2 (diver	sified accordi	ng to the Se	ecurities and	Yes	[]	No [Х
	1			2				Deel	3	41	1
	CUSIP#		Name of	Mutual Fund					/Adjus ing Va		
	29.2999 - Total							•		0	
29.3	For each mutual fund listed	in the table above, complete the following	ng schedule:	2			3 Amount of Mut Fund's Book/Adj	usted	4		
	Name of Mutua	al Fund (from above table)	Na	ame of Significa Mutual		the	Carrying Valu Attributable to Holding		Date Valua		
30.	Provide the following inform statement value for fair val	ation for all short-term and long-term boue.	onds and all p	oreferred stocks.	Do not subs	titute amort	ized value or				
				1	2		3 Excess of Statement	1			
				ent (Admitted) Value	Fair Val	0	ver Fair Value (-), or Fair Value over Statement (+)				
	30.1 Bonds			354,719,168		031,354	(3,687,814)			
				0		0	0				
	30.3 Totals			354,719,168	351,	031,354	(3,687,814)			
30.4	For those securities that had the NAIC SVO ISIS database	thods utilized in determining the fair valued prices in the NAIC SVO ISIS database ase, pricing was obtained from HUB which	e, those price ch is an exte	rnal data source	s vendor. HU	B utilizes va	arious pricing				
31.1	Was the rate used to calcula	ate fair value determined by a broker or	custodian fo	r any of the secu	ırities in Sche	dule D?		Yes	[]	No [χ
31.2		does the reporting entity have a copy of sed as a pricing source?							[]	No [

32.2 If no, list exceptions:

OTHER

Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?	\$	0	
List the name of the organization and the amount paid if any such payment represented 25% or more of the to service organizations and statistical or rating bureaus during the period covered by this statement.	otal payments to trade a	associations,	
1 Name	2 Amount Paid		
Amount of payments for legal expenses, if any?		\$	0
List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment the period covered by this statement.	nents for legal expenses	5	
1	2		
Name	Amount Paid		
Amount of payments for expenditures in connection with matters before legislative bodies, officers or department	nents of government, if a	any?\$	0
	nt.		
1	2		
Name	Amount Paid		
	List the name of the organization and the amount paid if any such payment represented 25% or more of the to service organizations and statistical or rating bureaus during the period covered by this statement. 1 Name Amount of payments for legal expenses, if any? List the name of the firm and the amount paid if any such payment represented 25% or more of the total paymenting the period covered by this statement. 1 Name Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of the firm and the amount paid if any such payment represented 25% or more of the total payment represented 2	List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade a service organizations and statistical or rating bureaus during the period covered by this statement. 1	Amount of payments for legal expenses, if any?

PART 2 - HEALTH INTERROGATORIES

1.1		the reporting entity have any direct Medicare Supplement Insurance in force					
1.2		indicate premium earned on U.S. business only.					
1.3		portion of Item (1.2) is not reported on the Medicare Supplement Insurance l Reason for excluding	Experience Exhibit?	.\$0			
	1.51 1	Neason for excluding					
1.4	Indica ²	te amount of earned premium attributable to Canadian and/or Other Alien pr	ot included in Item (1.2) above	s 0			
1.5		ndicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above					
1.6		tie total incurred claims on all Medicare Supplement insurance Iual policies:	Most current three years:	.\$ 0			
1.0	marvia	idal policies.	1.61 Total premium earned	e 0			
			1.62 Total incurred claims				
			1.63 Number of covered lives				
			All years prior to most current three years:				
			1.64 Total premium earned	.\$0			
			1.65 Total incurred claims	.\$0			
			1.66 Number of covered lives	0			
1.7	Groun	policies:	Most current three years:				
1.7	Group	policies.	-	ф <u>О</u>			
			1.71 Total premium earned				
			1.72 Total incurred claims	.\$0			
			1.73 Number of covered lives				
			All years prior to most current three years:				
			1.74 Total premium earned	.\$0			
			1.75 Total incurred claims	.\$0			
			1.76 Number of covered lives	0			
2.	Health	n Test:					
			1 2 Current Year Prior Year				
			Current Year Prior Year				
		Premium Numerator					
		Premium Denominator					
	2.3	Premium Ratio (2.1/2.2)	1.0001.000				
	2.4	Reserve Numerator					
	2.5	Reserve Denominator					
	2.6	Reserve Ratio (2.4/2.5)	1.0001.000				
3.1		ne reporting entity received any endowment or gift from contracting hospitals ned when, as and if the earnings of the reporting entity permits?		Yes [] No [X]			
3.2		give particulars:					
4.1	Have depe	copies of all agreements stating the period and nature of hospitals', physicia ndents been filed with the appropriate regulatory agency?	ns', and dentists' care offered to subscribers and	Yes [X] No []			
4.2	If not p	previously filed, furnish herewith a copy(ies) of such agreement(s). Do these	agreements include additional benefits offered?	Yes [] No [X]			
5.1	Does	the reporting entity have stop-loss reinsurance?		Yes [] No [X]			
5.2	Stop-lo	explain: oss reinsurance is not required given the nature of the products currently wri der contracts contain hold-harmless clauses.	itten by the Company and the underlying				
5.3	Mavim	num retained risk (see instructions)	5.31 Comprehensive Medical	s n			
0.0	IVIGAIIII	Totaliou non (occ mondellono)	5.32 Medical Only				
			5.33 Medicare Supplement				
			5.34 Dental & Vision	0			
			5.35 Other Limited Benefit Plan	\$0			
			5.36 Other	.\$0			
6.	hold l agree	ibe arrangement which the reporting entity may have to protect subscribers a harmless provisions, conversion privileges with other carriers, agreements v ements: narmless clauses in provider agreements.	vith providers to continue rendering services, and any other				
7.1	Does t	the reporting entity set up its claim liability for provider services on a service	date basis?	Yes [X] No []			
7.2	If no, g	give details					
8.	Provid	le the following information regarding participating providers:	8.1 Number of providers at start of reporting year . 8.2 Number of providers at end of reporting year				
9.1	Does t	the reporting entity have business subject to premium rate guarantees?		Yes [] No [X]			
9.2	If yes,	direct premium earned:	9.21 Business with rate guarantees between 15-36 months. 9.22 Business with rate guarantees over 36 months				

10.1	1.1 Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts?							[]
10.2	If yes:		1	0.21 Maximum am	ount payable bonus	.00	¢ 1'	3 087 735
10.2	ii yes.				ally paid for year boi			
					nount payable withho			
			1	U.24 Amount actua	ally paid for year wit	nnoids		4//,/91
11.1	Is the reporting entity organized as:							
					al Group/Staff Mode		Yes [] N	
				11.13 An Indivi	dual Practice Assoc	ciation (IPA), or, .	Yes [] N	
				11.14 A Mixed	Model (combination	of above)?	Yes [X] N	lo []
11.2	Is the reporting entity subject to Statutory Minimu	um Capital and Surp	olus Requirements	?			Yes [X] No	o []
11.3	If yes, show the name of the state requiring such							Arkansas
11.4	If yes, show the amount required.							100,000
11.5	Is this amount included as part of a contingency	reserve in stockhold	der's equity?				Yes [] No	[X]
11.6	If the amount is calculated, show the calculation							
	Arkansas Statutes § 23-76-108							
	Ÿ							
12.	List service areas in which reporting entity is lice	nsed to operate:						
			1					
			Name of Service					
		ma, Arkansas, Colo		,	, ,			
		s, Kentucky, Maine,						
		, New Mexico, New			· ·			
	'	/Ivania, South Caro						
10.1	Decree of the control of the factor of the control						v	
13.1	Do you act as a custodian for health savings acc	counts?					Yes [] No) [X]
13.2	If yes, please provide the amount of custodial fu	nds held as of the re	enorting date				\$	Λ
10.2	in yee, predeed provide the amount of edelodian id	ndo noid do or the re	pporting date:				V	
13.3	Do you act as an administrator for health saving	s accounts?					Yes [] No	[X]
13.4	If yes, please provide the balance of funds admi	nistered as of the re	porting date				\$	0
14.1	Are any of the captive affiliates reported on Sche		orized reinsurers?			Yes [] No [X]	N/A []
14.2	If the answer to 14.1 is yes, please provide the form	ollowing:						
	1	2	3	4	Assets	Supporting Reserve	e Credit	
		NAIC			5	6	7	
	October Name	Company	Domiciliary	Reserve	Letters of	Trust	0.11	
	Company Name	Code	Jurisdiction	Credit	Credit	Agreements	Other	_
15.	Provide the following for individual ordinary life in	nsurance* policies (l	U.S. business only) for the current ye	ar (prior to reinsura	nce assumed or		
	ceded):							•
					Direct Premium Writ			
					Total Incurred Claim			
				15.3 N	Number of Covered	Lives		0
		** "		In alcoder				
	*Ordinary Life Insurance Includes Term(whether full underwriting, limited underwriting, jet issue, "short form app")							
		underwriting, iimite ner full underwriting,				 		
		or without seconda		ig, jet issue, SHOLL	i ioiiii app)			
	,	th or without second	, , , , , , , , , , , , , , , , , , , ,					
	· · · · · · · · · · · · · · · · · · ·	I Life (with or withou		antee)				

FIVE-YEAR HISTORICAL DATA

			0.0.0.07			
		1 2016	2 2015	3 2014	4 2013	5 2012
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	1,029,490,809	900,901,751	646,874,788	565,861,329	502,425,732
2.	Total liabilities (Page 3, Line 24)				225,316,500	177,849,097
3.	Statutory minimum capital and surplus requirement				145 , 034 , 704	90,065,236
4.	Total capital and surplus (Page 3, Line 33)					324,576,635
	Income Statement (Page 4)			, , ,	,,,,,	, , ,
5.	Total revenues (Line 8)	3.705.330.964	3.290.271.397	2.985.409.175	2.464.372.875	1.649.234.962
6.	Total medical and hospital expenses (Line 18)					
7.	Claims adjustment expenses (Line 20)					
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)					
10.	Net investment gain (loss) (Line 27)					
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)					
12.	Cash Flow (Page 6)		90,007,200		01,042,100	102,010,000
12	Net cash from operations (Line 11)	3/15 031 673	81 640 780	(22 127 886)	6/ 161 108	120 /23 500
13.	, , ,		01,040,703	(22, 127,000).	04, 101, 130	129,425,509
4.4	Risk-Based Capital Analysis	400 064 000	015 151 707	240 504 042	240 544 920	224 576 625
14.	Total adjusted capital					
15.	Authorized control level risk-based capital	114,581,564	98, 102,409	91,953,727		45,032,618
	Enrollment (Exhibit 1)	070.004	050 040	040.000	040 040	00.740
16.	Total members at end of period (Column 5, Line 7)					
17.	Total members months (Column 6, Line 7)	3,205,692 [.	3,046,126	2,8/9,915	2,269,423	1, 108, 862
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)	76.5	84.6	82.8	81.8	71.0
20.	Cost containment expenses	2.2	2.5	1.9	0.8	3.3
21.	Other claims adjustment expenses					
22.	Total underwriting deductions (Line 23)	89.3	97.7	95.7	94.9	85.6
23.	Total underwriting gain (loss) (Line 24)	10.7	2.3	4.3	5.1	14 . 4
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 13, Col. 5)	192,118,016	139,918,155	85,078,151	40,759,494	76 , 131 , 144
25.	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]	189,086,791	92,176,407	96,322,547	100,016,380	115,267,029
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	0
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					0
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)				0	0
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)				0	0
30.	Affiliated mortgage loans on real estate				0	0
31.	All other affiliated					0
32.	Total of above Lines 26 to 31					
33.	Total investment in parent included in Lines 26 to					
	31 above. If a party to a merger, have the two most recent years of	0	0	0	0	0

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories


				Allocated by	States and T					
		1	2	2	4	Direct Bus	iness Only	7	0	
			2	3	4	5 Federal	6	7	8	9
						Employees				
						Health	Life & Annuity			
			Accident &			Benefits	Premiums &	Property/	Total	
		Active	Health	Medicare	Medicaid	Plan	Other	Casualty	Columns 2	Deposit-Type
	States, etc.	Status	Premiums	Title XVIII	Title XIX	Premiums	Considerations	Premiums	Through 7	Contracts
1.	Alabama AL	L	0	1,477,080	0	0	0	0	1,477,080	0
2.	Alaska AK	N	0	0	0	0	0	0	0	0
3.	Arizona AZ	N	0	0	0	0	0	0	0	0
4.	Arkansas AR	L	0	421,489,937	0	0	0	0	421,489,937	0
5.	California CA	N	0	0	0	0	0	0	0	0
6.	Colorado CO	L	0	9,771	0	0	0	0	9,771	0
7.	Connecticut CT	N	0	0	0	0	0	0	0	0
8.	Delaware DE	N	0	0	0	0	0	0	0	0
9.	District of Columbia DC	N	0	0	0	0	0	0	0	0
10.	Florida FL	L	0	7,782,734	0	0	0	0	7,782,734	0
11.	Georgia GA	L	0	1,439,486,376	0	0	0	0	1,439,486,376	0
12.	Hawaii HI	N	0	0	0	0	0	0	0	0
13.	Idaho ID	N	0	0	0	0	0	0	0	0
14.	Illinois II	L	0	7,692,959	0	0	0	0	7,692,959	0
15.	Indiana IN	Ī	0	6,317,213	0	0	0	0	6,317,213	0
	lowa IA	Ī	0	0	0	0	0	0	0	0
	Kansas KS	L	0	0	0	0	0	0	0	0
18.	Kentucky KY	Ī	0	0	0	0	0	0	n	n
	Louisiana LA	N	0	0	0	0	0	0	0	n
	Maine ME	I	0	(4,035)	0	0	0	0	(4,035)	0
21.	Maryland MD	N	0	(4,000)	0	0	0	0 0	(4,000)	n
	Massachusetts MA	IV	0	(125, 121)	0	0	0	0	(125, 121)	0
23.	Michigan MI	N	0	(123, 121)	0	0	0	0 0	(125, 121)	n
23. 24.	Minnesota MN	IV	0	0	0	0	0	0 0	, <u>0</u>	, , , , , , , , , , , , , , , , , , ,
24. 25.	Mississippi MS	NI	0	0	U		0	0 0		ļ
26.		N	0	502,503,189		0		 0	502,503,189	
20. 27.		L			0			0 0		0
		N	0	0					0	J
28.	Nebraska NE	N.	0	0		0		0	0	J
	Nevada NV	N	0	0	0	0	0	0	0	0
	New Hampshire NH	<u>-</u>	0	13,687,103	0	0	0	0	13,687,103	
	New Jersey NJ	<u>-</u>	0	9,888,375	0	0	0	0	9,888,375	0
32.	New Mexico NM	<u>L</u>	0	954,239	0	0	0	0	954,239	0
	New York NY	L	0	0	0	0	0	0	0	0
34.	North Carolina NC	L	0	0	0	0	0	0	0	0
	North Dakota ND	N	0	0	0	0	0	0	0	0
36.	Ohio OH	L	0	2,654,629	0	0	0	0	2,654,629	0
37.	Oklahoma OK	L	0	0	0	0	0	0	0	0
38.	Oregon OR	N	0	0	0	0	0	0	0	0
39.	Pennsylvania PA	L	0	737,284	0	0	0	0	737,284	0
40.	Rhode Island RI	N	0	0	0	0	0	0	0	0
41.	South Carolina SC	L	0	1,266,765,940	0	0	0	0	1,266,765,940	0
42.	South Dakota SD	NN	0	0	0	0	0	0	0	0
43.	Tennessee TN	N	0	0	0	0	0	0	0	0
44.	Texas TX	L	0	(35,781)	0	0	0	0	(35,781)	0
45.	Utah UT	N	0	0	0	0	0	0	0	0
	Vermont VT	N	0	0	0	0	0	0	0	0
	Virginia VA	L	0	381,559	0	0	0	0	381,559	0
	Washington WA	L	0	0	0	0	0	0	0	0
	West Virginia WV	N	0	0	0	0	0	0	0	0
	Wisconsin WI	N	n	0	n	n	n	n	n	n
	Wyoming WY	N.	n		0	0	0	0	n	0
	American Samoa AS	N	n	0	n	n	n	 n	n	n
	Guam GU	N N	n	n l	n	0	n	0	n	n
	Puerto Rico PR	N	0	ا ۵	0	0	n l	 ۱	n	n
	U.S. Virgin Islands VI	N	0	n	0	0	0	0	n	n
	Northern Mariana							0		1
55.	Islands MP	NN	0	0	0	0	0	0	0	0
57.	Canada CAN	N	0	0	0	0	0	0	0	n
58.	Aggregate other									
	alien OT	XXX	0	0	0	0	0	0	0	0
59.	Subtotal	XXX	0	3,681,663,451	0	0	L 0	0	3,681,663,451	0
60.	Reporting entity		-							
	contributions for Employee									
	Benefit Plans	XXX	0	0	0	0	0	0	0	0
61.	Total (Direct Business)	(a) 25	0	3,681,663,451	0	0	0	0	3,681,663,451	0
	DETAILS OF WRITE-INS									
58001.		XXX					ļ		4	
58002.		XXX								_
58003.		XXX								_
58998.	Summary of remaining									
	write-ins for Line 58 from						<u> </u>			
	overflow page	XXX	0	0	0	0	0	0	0	ļ0
58999.	Totals (Lines 58001 through									
	58003 plus 58998)(Line 58	3001	^		^	^		^	_	_
<u></u>	above)	XXX	0	0	0	0	0	0	0	0
1 \ 1 \	sed or Chartered - Licensed Inst	urance Carrier o	or Domiciled PD(2. (D) Pagistared	- Non-domiciled	PDCc. (U) Quali	tied - Ouglified or	Accredited Dai	oouror: (E) Eligible	


⁽L) Licensed or Chartered - Licensed Insurance Carrier or Domiciled RRG; (R) Registered - Non-domiciled RRGs; (Q) Qualified - Qualified or Accredited Reinsurer; (E) Eligible - Reporting Entities eligible or approved to write Surplus Lines in the state; (N) None of the above - Not allowed to write business in the state.


Explanation of basis of allocation by states, premiums by state, etc.


Premiums are allocated by state based upon the residence of the member.


(a) Insert the number of L responses except for Canada and Other Alien.















PART 1 – ORGANIZATIONAL CHART





40.5











PART 1 – ORGANIZATIONAL CHART

Notes

All legal entities on the Organization Chart are Corporations unless otherwise indicated.

- (1) Entity is a Limited Liability Company
- (2) Entity is a Partnership
- (3) Entity is a Non-Profit Corporation
- (4) Control of the Foundation is based on sole membership, not the ownership of voting securities
- (5) COI Participações S.A. is 87.270% owned by Esho Empresa de Serviços Hospitalares S.A. and 12.729% owned by COIPAR Participações S.A.
- 6) UnitedHealth Group Information Services Private Limited is 100% owned by Optum Global Solutions (India) Private Limited. UnitedHealth International, Inc. holds 10 shares as a nominee shareholder.
- (7) UnitedHealthcare India Private Limited is 99.9935% owned by UnitedHealthcare International II B.V. and 0.0065% owned by UnitedHealth International, Inc.
- (8) General partnership interests are held by United HealthCare Services, Inc. (89.77%) and by UnitedHealthCare, Inc. (10.23%). United HealthCare Services, Inc. also holds 100% of the limited partnership interests. When combining general and limited partner interests, United HealthCare Services, Inc. owns 94.18% and UnitedHealthCare, Inc. owns 5.83%.
- (9) Branch office located in Abu Dhabi, UAE.
- (10) WellMed Medical Management, Inc. is 80% owned by Collaborative Care Holdings, LLC and 20% owned by WMG Healthcare Partners, L.P.
- (11) Seisa Serviços Integrados de Saúde Ltda is 99.99% owned by Amil Assistência Médica Internacional S.A. and 0.000007% owned by Cemed Care – Empresa de Atendimento Clinico Geral Ltda.
- (12) Optum Health & Technology (India) Private Limited is 99.996% owned by OptumHealth International B.V. and 0.004 % owned by United Behavioral Health.
- (13) INSPIRIS of Texas Physician Group is a Texas non-profit (taxable) whose sole member is Inspiris Services Company.
- (14) PrimeCare of Citrus Valley, Inc. is 80% owned by PrimeCare Medical Network, Inc. and 20% owned by Citrus Valley Medical Associates, Inc.
- (15) Optum Clinics Holdings, Inc. is 97.2% owned by Collaborative Care Holdings, LLC and 2.8% is owned by external shareholders.
- (16) Optum Global Solutions (India) Private Limited is 99.9% owned by Optum Global Solutions International B.V. and 0.1% owned by UnitedHealth International. Inc.
- (17) Amico Saúde Ltda. is 98.87947% owned by Amil Assistência Médica Internacional S.A. and 1.12053% owned by Cemed Care Empresa de Atendimento Clinico Geral Ltda.
- (18) Esho Empresa de Serviços Hospitalares S.A. is 99.577% owned by Amil Assistência Médica Internacional S.A.and 0.0185976% owned by Treasury Shares and .4044814% owned by external shareholders.
- (19) Etho Empresa de Technologia Hospitalar Ltda. 82.64% owned by Amil Assistência Médica Internacional S.A.and 17.357% owned by an external shareholder.
- (20) Orthology, Inc. is 80% owned by UnitedHealth Group Ventures, LLC and 20% owned by external shareholders.
- (21) Medalliance Net Ltda. is owned 99.999985% by Optum Health & Technology Serviços do Brasil Ltda. and 0.000015% by UHG Brasil Participações S.A.
- (22) Branch offices in Iraq and Uganda.
- (23) Cemed Care Empressa de Átendimento Clínico Geral Ltda. Is 99.9999995% owned by Amil Assistência Médica Internacional S.A. and 0.000005% owned by Amico Sáude Ltda.
- (24) Optum 360, LLC is 69% owned by Optum Rocket, Inc; the remaining 31% is owned by external holders.
- (25) Optum Health & Technology Serviços do Brasil Ltda. is 99.9964% owned by Optum Global Solutions International B.V. and .0036% owned by OptumInsight, Inc.

- (26) Bosque Medical Center Ltda. is 81.65320% owned by Amil Assistência Médica Internacional S.A.and 18.34680% owned by Esho – Empresa de Servicos Hospitalares S.A.
- (27) AHJV, Inc. is 75% owned by NAMM Holdings, Inc. and 25% owned by Humana, Inc.
- (28) Real Appeal, Inc. is majority-owned by UHG or one of its affiliates and the remaining 2% is owned by Real Appeal Management.
- (29) Optum Global Solutions (Philippines), Inc. is 99.992% owned by Optum Global Solutions International B.V., and the remaining 0.008% is held by the company's directors.
- (30) Amil Clinical Research Participações Ltda. is 99.95% owned by Amil Lifesciences Participações Ltda. and 0.05% owned by Cemed Care – Empresa de Atendimento Clinico Geral Ltda.
- (31) Imed Star Serviços de Desempenho Organizacional Ltda. is 99.99998% owned by Optum Health & Technology Serviços do Brasil Ltda and 0.00002% owned by UHG Brasil Participações S.A.
- (32) Hospital de Clínicas de Jacarepaguá Ltda. is 99.999996% owned by Esho Empresa de Serviços Hospitalares S.A. and 0.000004% is owned by Cemed Care – Empresa de Atendimento Clínico Geral Ltda.
- (33) Hospital Alvorada Taguatinga Ltda.is 79.62822% owned by Amil Assistência Médica Internacional S.A, 20.37178% by Bosque Medical Center Ltda.
- (34) Amil Lifesciences Participações Ltda. Is 99.999685% owned by Amil Assistência Médica Internacional S.A and 0.000315% owned by Cemed Care Empressa de Atendimento Clinico Geral Ltda.
- (35) FrontierMEDEX Kenya Limited is 99.9% owned by Frontier MEDEX Limited and 0.1% owned by UnitedHealthcare International I B.V.
- (36) Optum360 Services, Inc. is 69% owned by Optum Rocket, Inc. and 31% owned by two external interest holders.
- (37) The limited partners of UnitedHealth Group International, L.P. include FMG Holdings, LLC (14.8145%), Hygeia Corporation (DE) (0.2012%) and UnitedHealth Group Incorporated (84.9843%). UnitedHealth Group International GP is the general partner of UnitedHealth Group International, L.P.
- (38) Polar II Fundo de Investimento em Participações is a Brazilian private equity investment fund incorporated in the form of a closed-end condominium.
- (39) UnitedHealthcare International III S.á r.l. is 69.995% owned by UnitedHealthcare Europe S.á r.l. and 30.005% owned by UnitedHealthcare International II S.á r.l.
- (40) Amil Assistência Médica Internacional S.A. is 90.23% owned by Polar II Fundo de Investimento em Participações and the remaining 9.77% is owned by the former controlling shareholders of Amil Assistência Médica Internacional S.A.
- (41) Lusíadas A.C.E. is 70% owned by Lusíadas, SGPS, S.A., 10% owned by Lusíadas Parcerias Cascais, S.A., and 20% owned by Lusiadas, S.A.
- (42) Centro Médico PJ Ltda. is 99.99% owned by Esho Empresa de Serviços Hospitalares S.A. and 0.01% is owned by Cemed Care – Empresa de Atendimento Clínico Geral Ltda.
- (43) Frontier Medex Tanzania Limited is 99% owned by Frontier MEDEX Limited. The remaining 1% is owned by a former officer of Frontier MEDEX Limited and is being transferred to UnitedHealthcare International I BV.
- (44) Optum Solutions do Brasil Tecnologia e Serviços de Suporte Ltda., is 99.999998% owned by Optum Global Solutions International B.V.and 0.00002% owned by OptumHealth International B.V.
- (45) Multiangio Ltda. is 68% owned by Esho Empresa de Serviços Hospitalares S.A. and the remaining 32% is owned by external shareholders.
- (46) Polo Holdco, LLC is 80.1% owned by Collaborative Care Holdings, LLC and the remaining 19.9% being owned by an outside third party.
- (47) Excellion Serviços Biomédicos Ltda is 99.999997% owned by Esho Empresa de Serviços Hospitalares S.A. and 0.000003% is owned by Cemed Care - Empresa de Atendimento Clínico Geral Ltda.

- (48) Hospital Samaritano de São Paulo Ltda. is 99.9999998% owned by Esho Empresa de Serviços Hospitalares S.A.and the remaining 0.0000002% is owned by Hospital Alvorada Taguatinga Ltda.
- (49) Branch office located in Hong Kong.
- (50) Dental Center Serviços Odontológicos Ltda. is 100% owned by Seisa Servicos Integrados de Sáude Ltda.
- (51) TBD
- (52) WESTMED Practice Partners LLC is 86.15% owned by Collaborative Care Holdings, LLC and 13.85% owned by external shareholders.
- (53) ProHEALTH Medical Management, LLC is 80% owned by Collaborative Care Holdings, LLC and 20% owned by an external shareholder.
- (54) ProHEALTH Fitness of Lake Success, LLC is 82.62% owned by ProHEALTH Medical Management, LLC and 17.38% by an external shareholder.
- (55) Hospital Maternidade Promater Ltda is 99.99% owned by Esho Empresa de Servicos Hospitalares S.A. and 0.00006% owned by Cemed Care Empressa de Atendimento Clínico Geral Ltda.
- (56) Hospital Geral e Maternidade Madre Maria Theodora Ltda. is 99.9999% owned by Esho Empresa de Serviços Hospitalares S.A. and 0.00001% owned by Cemed Care Empressa de Atendimento Clínico Geral Ltda.
- (57) Angiografia e Hemodinâmica Madre Theodora Ltda. is 50% owned by Hospital Geral e Maternidade Madre Maria Theodora Ltda. and 50% owned by 28 individual partners.
- (58) Guardian Health Systems Limited Partnership is 99.95% owned by AxelaCare Holdings, Inc. with the remaining 0.05% interest as a limited partner being held by AxelaCare Health Solutions. LLC.
- (59) TeamMD Holdings, Inc., a Delaware corporation, was formed as an 80% owned subsidiary of UnitedHealth Group Ventures, LLC, a Delaware limited liability company. The remaining 20% is owned by external shareholders.
- (60) Hospitais Associados de Pernambuco Ltda. is 90% owned by Esho Empresa de Serviços Hospitalares S.A. and 10% is owned by an external shareholder
- (61) Topimagem Diagnóstico por Imagem Ltda.is 89% owned by Esho Empresa de Serviços Hospitalares S.A., and the remaining 11% interest is owned by external shareholders.
- (62) Dilab Medicina Nuclear Ltda is 85% owned by Esho Empresa de Serviços Hospitalares S.A. and the remaining 15% is owned by external shareholders.
- (63) WellMed Networks DFW, Inc. is 50% owned by WellMed Networks, Inc. and 50% owned by USMD Inc. WellMed Medical Management, Inc. controls 100% of WellMed Networks -DFW.
- (64) Clinica Oftalmologica Danilo de Castro Sociedade Simples is 99.99% owned by Hospital Alvorada de Taguatinga Ltda. and the remaining 0.333333% is owned by Lotten-Eyes Oftalmologia Clinica e Cirurgica Ltda.
- (65) Lotten-Eyes Oftalmologia Clinica e Cirurgica Ltda. is 99.99% owned by Hospital Alvorada de Taguatinga Ltda.and the remaining 0.000012% is owned by Esho – Empresa de Serviços Hospitalares S.A.
- (66) CMO Centro Médico de Oftalmologia S/S Ltda. is 99% owned by Hospital Alvorada de Taguatinga Ltda.and the remaining is owned by Lotten-Eyes Oftalmologia Clinica e Cirurgica I tda
- (67) MedSynergies North Texas, LLC. is 70% owned by PHYS Holding LLC. and the remaining 30% is owned by PhyServe Holdings, LLC.
- (68) Elual Participações S.A. is 60% owned by Amil Assistência Médica Internacional S.A. and 40% by Esho – Empresa de Servicos Hospitalares S.A.
- (69) Hospital Santa Helena S.A. is 65.21% owned by Elual Participações S.A. and 34.79% owned by Esho – Empresa de Serviços Hospitalares S.A.
- (70) Santa Helena Assistência Médica S.A. is 65.21% owned by Elual Participações S.A. and 34.79 owned by Amil Assistência Médica Internacional S.A

OVERFLOW PAGE FOR WRITE-INS

Additional Write-ins for Underwriting and Investment Exhibit Part 3 Line 25

Additional write-ins for underwriting and investment exhibit Part 5 Line 25							
		Claim Adjustment Expenses		3	4	5	
		1	1 2				
		Cost	Other Claim	General			
		Containment	Adjustment	Administrative	Investment		
		Expenses	Expenses	Expenses	Expenses	Total	
2504.	Miscellaneous Losses	4,353	2,972	158,657	0	165,982	
2505.	Professional Fees/Consulting	552,021	376,852	1,507,112	0	2,435,985	
2506.	Sundry General Expenses	3,434,755	2,344,829	10,952,016	0	16,731,600	
2597.	Summary of remaining write-ins for Line 25 from						
	overflow page	3,991,129	2,724,653	12,617,785	0	19,333,567	

ALPHABETICAL INDEX

ANNUAL STATEMENT BLANK

Analysis of Operations By Lines of Business	
Assets	
Cash Flow	
Exhibit 1 - Enrollment By Product Type for Health Business Only	
Exhibit 2 - Accident and Health Premiums Due and Unpaid	
Exhibit 3 - Analysis of Health Care Receivables Collected and Accrued.	
Exhibit 4 - Claims Unpaid and Incentive Pool, Withhold and Bonus	
Exhibit 5 - Amounts Due From Parent, Subsidiaries and Affiliates	
Exhibit 6 - Amounts Due To Parent, Subsidiaries and Affiliates	
Exhibit 7 - Part 1 - Summary of Transactions With Providers	
Exhibit 7 - Part 2 - Summary of Transactions With Intermediaries	
Exhibit 8 - Furniture, Equipment and Supplies Owned	
Exhibit of Capital Gains (Losses)	
Exhibit of Net Investment Income	
Exhibit of Nonadmitted Assets	16
Exhibit of Premiums, Enrollment and Utilization (State Page)	30
Five-Year Historical Data	29
General Interrogatories	27
Jurat Page	1
Liabilities, Capital and Surplus	3
Notes To Financial Statements	26
Overflow Page For Write-ins	
Schedule A - Part 1	E01
Schedule A - Part 2	E02
Schedule A - Part 3	
Schedule A - Verification Between Years	
Schedule B - Part 1	
Schedule B - Part 2	
Schedule B - Part 3	
Schedule B - Verification Between Years	
Schedule BA - Part 1	
Schedule BA - Part 2	
Schedule BA - Part 3	
Schedule BA - Verification Between Years	
Schedule D - Part 1A - Section 1	SI05
Schedule D - Part 1A - Section 1	······································
Schedule D - Part 2 - Section 1	
Schedule D - Part 2 - Section 2	
Schedule D - Part 3	
Schedule D - Part 4	
Schedule D - Part 5	
Schedule D - Part 6 - Section 1	
Schedule D - Part 6 - Section 2	
Schedule D - Summary By Country	S104
Schedule D - Verification Between Years	SI03
Schedule DA - Part 1	E17
Schedule DA - Verification Between Years	SI10
Schedule DB - Part A - Section 1	E18
Schedule DB - Part A - Section 2	E19
Schedule DB - Part A - Verification Between Years	SI11
Schedule DB - Part B - Section 1	E20
Schedule DB - Part B - Section 2	
Schedule DB - Part B - Verification Between Years	
Schedule DB - Part C - Section 1	
Schedule DB - Part C - Section 2	
Schedule DB - Part D - Section 1	
Schedule DB - Part D - Section 2	
Schedule DB - Verification	
Schedule DL - Part 1	
Schedule DL - Part 2	
Schedule E - Part 1 - Cash	
Schedule E - Part 2 - Cash Equivalents	
Schedule E - Part 3 - Special Deposits	
Schedule E - Verification Between Years	SI15

ANNUAL STATEMENT BLANK (Continued)

Schedule S - Part 1 - Section 2	31
Schedule S - Part 2	32
Schedule S - Part 3 - Section 2	33
Schedule S - Part 4	34
Schedule S - Part 5	35
Schedule S - Part 6	
Schedule S - Part 7	37
Schedule T - Part 2 - Interstate Compact	
Schedule T - Premiums and Other Considerations	38
Schedule Y - Information Concerning Activities of Insurer Members of a Holding Company Group	40
Schedule Y - Part 1A - Detail of Insurance Holding Company System	41
Schedule Y - Part 2 - Summary of Insurer's Transactions With Any Affiliates	42
Statement of Revenue and Expenses	4
Summary Investment Schedule	SI01
Supplemental Exhibits and Schedules Interrogatories	
Underwriting and Investment Exhibit - Part 1	8
Underwriting and Investment Exhibit - Part 2	9
Underwriting and Investment Exhibit - Part 2A	10
Underwriting and Investment Exhibit - Part 2B	11
Underwriting and Investment Exhibit - Part 2C	12
Underwriting and Investment Exhibit - Part 2D	13
Underwriting and Investment Exhibit - Part 3	14